

# The Relationship between Transmembrane Mucins, Ion Channels and PDZ Adaptor Proteins in the Small Intestine

Thaer Pelaseyed

Department of Medical Biochemistry  
Institute of Biomedicine  
Sahlgrenska Academy  
University of Gothenburg  
2012



UNIVERSITY OF GOTHENBURG

ISBN 978-91-628-8521-2  
URL: <http://hdl.handle.net/2077/29724>  
© Thaher Pelaseyed  
Department of Medical Biochemistry  
Institute of Biomedicine  
Sahlgrenska Academy  
University of Gothenburg  
SWEDEN

Printed by Kompendiet  
Gothenburg, Sweden 2012

To my beloved family.



# ABSTRACT

Thaer Pelaseyed

Department of Medical Biochemistry, Institute of Biomedicine  
Sahlgrenska Academy at University of Gothenburg  
Göteborg, Sweden

The human body is continuously exposed to challenges from the surrounding world. In analogy with the skin, mucus is a well-organized and highly regulated barrier composed of polymeric and *O*-glycosylated mucins that protects luminal organs such as the gastrointestinal tracts from the outer milieu. As part of a first defensive barrier, the secreted mucins entrap pathogens and act as a network for antiseptic enzymes and proteins. A second barrier is the dense glycocalyx which is composed of transmembrane mucins anchored to the apical membrane of cells.

The focus of this thesis was to identify novel interactions between transmembrane mucins and cytoplasmic PDZ adaptor proteins and to determine the role of these interactions in mucin expression and regulation. Furthermore, the interplay between transmembrane mucins and ion channels expressed in the small intestine was explored. Finally, the stability of the SEA domain in transmembrane mucins was assessed.

Using different techniques in molecular biology and confocal imaging, this thesis proves that the transmembrane mucins MUC3 and MUC17 bind to PDZ adaptor proteins that are interaction partners for two intestinal ion channels, namely CFTR and NHE3. Specifically, MUC17 is retained in the apical surface of enterocytes by PDZK1. In analogy with acute  $\text{Ca}^{2+}$ -mediated regulation of NHE3 and CFTR, the cholinergic agonist carbachol induces endocytosis of MUC17, concomitant with NHE3 internalization and CFTR recruitment to the cell surface. This thesis also demonstrates that the expression of MUC3 is counter-regulated by CFTR via a *trans*-Golgi-resident PDZ adaptor protein called GOPC. Finally, using atomic force microscopy, it is demonstrated that the SEA domain of transmembrane mucins protects the apical cell membrane by acting as a breaking point upon mechanical stress.

In summary, the results from this thesis deliver new evidence regarding the relationship between transmembrane mucins and ion channels. These novel networks cast light on important cellular processes, involving the formation of physical barriers coupled to fluid and mucin secretion, that occur in response to native and foreign provocations.

Keywords: intestine, mucin, MUC3, MUC17, SEA, PDZK1, GOPC, CFTR, NHE3

## List of papers

---

This thesis is based on the following studies, referred to in the text by their Roman numerals.

- I. Malmberg, E. K., Pelaseyed, T., Petersson, A. C., Seidler, U. E., De Jonge, H., Riordan, J. R. and Hansson, G. C. (2008) **The C-terminus of the transmembrane mucin MUC17 binds to the scaffold protein PDZK1 that stably localizes it to the enterocyte apical membrane in the small intestine.** *Biochem. J.* 410, 283-289
- II. Pelaseyed, T. and Hansson, G. C. (2011) **CFTR anion channel modulates expression of human transmembrane mucin MUC3 through the PDZ protein GOPC.** *J. Cell. Sci.* 124, 3074-3083
- III. Pelaseyed, T., Zäch, M., Petersson, Å. C., Svensson, F., Johansson, D.G.A., Hansson, G. C. **Unfolding dynamics of the mucin SEA domain probed by force spectroscopy suggest that it acts as a cell protective device**  
*Submitted.*
- IV. Pelaseyed, T., Gustafsson, J. K., Gustafsson, I. J., Hansson, G. C. **Carbachol-induced internalization of human transmembrane MUC17 mucin is concomitant with NHE3 internalization and CFTR externalization in enterocytes**  
*Manuscript.*

# Contents

---

|  |           |
|--|-----------|
| <b>Chapter 1: Introduction</b> . . . . .   | <b>9</b>  |
| The Mucus Barrier . . . . .  | 9         |
| PDZ Adapter Proteins . . . . .   | 16        |
| The ion channels of the small intestine . . . . .                                    | 18        |
| Carbachol, a cholinergic agonist . . . . .   | 22        |
| The brush border of enterocytes . . . . .  | 24        |
| Vesicle trafficking in polarized epithelial cells . . . . .                          | 25        |
| Trafficking of membrane-tethered mucins . . . . .                                    | 28        |
| Trafficking of CFTR and NHE3 . . . . .   | 29        |
| Aims of thesis . . . . .   | 31        |
| <b>Chapter 2: Methods</b> . . . . .  | <b>32</b> |
| Animals (Papers I and IV) . . . . .  | 32        |
| Antibodies (Papers I, II, and IV) . . . . .  | 32        |
| Atomic force microscopy (Paper III) . . . . .  | 33        |
| Labeling of surface glycoproteins (Paper IV) . . . . .                               | 33        |
| <b>Chapter 3: Results</b> . . . . .  | <b>34</b> |
| Transmembrane mucins are ligands for PDZ adaptor proteins (Paper I and II) . . . . . | 34        |
| Transmembrane mucins and ion channels are co-regulated (Paper II and IV) . . . . .   | 36        |
| SEA-type transmembrane mucins act as protective devices (Paper III) . . . . .        | 42        |
| <b>Chapter 4: Discussion</b> . . . . .   | <b>45</b> |
| Transmembrane mucins display specificity towards PDZ proteins . . . . .              | 45        |
| PDZ proteins regulate mucin expression and subcellular localization . . . . .        | 46        |
| Membrane mucins and ion channels are co- and counter-regulated . . . . .             | 47        |
| The SEA domain acts as a protective device . . . . .                                 | 49        |
| Future perspectives . . . . .  | 51        |
| <b>Populärvetenskaplig sammanfattning</b> . . . . .                                  | <b>53</b> |
| <b>Acknowledgements</b> . . . . .  | <b>55</b> |
| <b>References</b> . . . . .  | <b>57</b> |

## Abbreviations

---

|                  |   |                 |   |
|------------------|---|-----------------|---|
| AFM              | atomic force microscopy                                       | HA              | hemagglutinin   |
| AMOP             | adhesion-associated domain in MUC4 and other proteins         | I <sub>sc</sub> | short circuit current                                       |
| AP               | adaptor protein   | LE              | late endosomes  |
| BHK              | baby hamster kidney   | mAb             | monoclonal antibody   |
| Ca <sup>2+</sup> | calcium ion   | MDa             | megadalton  |
| CaCC             | calcium-activated chloride channels                           | MTOC            | microtubule organizing centers                              |
| cAMP             | cyclic adenosine monophosphate                                | MUC             | mucin   |
| CF               | cystic fibrosis   | NHE             | Na <sup>+</sup> /H <sup>+</sup> exchanger                   |
| CFTR             | cystic fibrosis transmembrane conductance regulator           | NHERF           | Na <sup>+</sup> /H <sup>+</sup> exchanger regulatory factor |
| cGMP             | cyclic guanosine monophosphate                                | NIDO            | nidogen homology region                                     |
| CK               | cysteine knot domain  | NMDA            | N-methyl d-aspartate  |
| ClC              | chloride channel type   | NTA             | nitriloacetate  |
| CME              | clathrin-mediated endocytosis                                 | pAb             | polyclonal antibody   |
| CT               | cytoplasmic tail  | PDZ             | PSD-95/Discs large/ZO-1                                     |
| EE               | early endosome  | PKC             | protein kinase C  |
| EEA1             | early endosome antigen 1                                      | PTS             | proline-, threonine-, and serine-rich                       |
| ER               | endoplasmic reticulum   | RE              | recycling endosomes   |
| GOPC             | golgi-associated PDZ and coiled-coil motif-containing protein | SEA             | sea urchin sperm protein, enterokinase, and agrin           |
| GSK              | glycogen synthase kinase                                      | TGN             | <i>trans</i> -Golgi network                                 |
|                  |   | vWC             | von Willebrand C domain                                     |
|                  |   | vWD             | von Willebrand D domain                                     |
|                  |   | Wt              | wildtype  |



# Introduction

# 1

## **The Mucus Barrier**


---

The human body is continuously exposed to chemical and mechanical stress from the surrounding world. The skin is a specialized keratinous barrier which protects the human body from these challenges as well as from pathogens. In analogy with the keratinized skin, luminal organs such as the gastrointestinal, respiratory, and urovaginal tracts are protected from the outer milieu. In these cavities the keratinized skin is substituted for a well-organized and highly regulated mucus barrier with protective, lubricative and biological functions [1]. As part of a first protective barrier, the mucus layer which covers surfaces of luminal organs is an important component of the innate immunity. Apart from constituting a physical barrier, the mucus plays a part as an extensive network for antimicrobial peptides and proteins.

## **Mucins**

Mucins are the major constituents of the mucus layer covering epithelial surfaces. Mucins are glycoproteins of high molecular weight, harboring large numbers of *O*-glycans on long domains composed of proline (Pro), serine (Ser) and threonine (Thr) amino acid residues, also called PTS domains [2]. The glycosylated PTS domain, called the mucin domain, accounts for approximately 80% of the molecular mass of a mucin glycoprotein. Initially, the amino acid sequences of the mucin domain were shown to be long repetitive sequences, thus they

were classified as tandem repeat regions [3, 4]. Tandem repeat regions varied in both length and sequence dependent on species and splice variants of individual mucins. However, more recent discoveries indicate that, as a result of a high frequency of irregularly scattered Ser and Thr residues in the PTS domain, not all mucin domains can be classified as tandem repeats [5]. Therefore, we use PTS domain as a more general terminology for *O*-glycosylated amino acid sequences in mucins. Due to the high density of the anchored *O*-glycans, mucins adopt a rigid extended, bottle-brush, conformation. Based on their structure, mucins are categorized into two distinct groups [6]. The gel-forming mucins are a category of mucins discharged from goblet cells or glands, giving rise to a luminal matrix of mucus [7, 8]. The second category of mucins consists of the membrane-tethered mucins which are characterized by a single-span transmembrane domain, anchoring the glycoprotein to the plasma membrane of epithelial cell, as summarized in Fig. 1 [9].



**Fig. 1.** Schematic drawing of the epithelial cells lining the small intestinal villi, covered with secreted mucins. The magnified view (right) displays microvilli protruding from the apical membrane of the enterocyte. The dense glycocalyx of transmembrane mucins has been suggested to act as a protective barrier.

### **Gel-forming mucins**

The secreted mucins are MUC2, MUC5AC, MUC5B, MUC6, and MUC7. All of these secreted glycoproteins form large and complex gel-like structures with the exception of the small non-gel-forming MUC7 found in saliva [10]. Four gel-forming mucin genes, *MUC2*, *MUC5AC*, *MUC5B* and *MUC6*, are clustered on human chromosome 11p15 [11]. These gel-forming mucins form polymers via their N- and C-termini that contain conserved von Willebrand D (vWD) domains [12]. Gel-forming mucins harbor long mucin domains that vary in length, amino acid sequence and glycosylation patterns. Cysteine-rich domains, also designated CysD domains, are dispersed along the mucin domains and are suggested to mediate non-covalent crosslinking between mucin molecules [13]. MUC2 is the major secreted mucin in the small intestine and colon. It is a 2.5 MDa large glycoprotein with *O*-linked glycans attached to hydroxyl amino acids in its PTS domain [2]. MUC2 dimerizes via its C-terminus in the endoplasmic reticulum (ER), followed by heavy *O*-glycosylation in the Golgi apparatus. Further polymerization of the glycoprotein takes place when trimers, held together via N-terminal disulfide bonds, polymerize in acidic secretory vesicles [14]. Besides two CysD domains in its mucin domain which is further flanked by N- and C-terminal vWD domains, MUC2 harbors a von Willebrand C domain (vWC) and a cysteine knot domain (CK) on its C-terminal end [15, 16].

### **Membrane-tethered mucins**

The membrane-tethered mucins MUC1, MUC3, MUC4, MUC12, MUC13, MUC16, MUC17, and MUC20, are type I transmembrane proteins and share common features such as mucin and cytoplasmic domains, while they differ in length, sequence and glycosylation patterns. They all have an N-terminal signal sequence,


allowing targeting of the membrane-tethered mucin to the secretory pathway. The signal sequence is followed by a PTS domain which is heavily decorated with *O*-glycans. The membrane-tethered mucins MUC1, MUC3, MUC12, MUC16, and MUC17 harbor EGF-like domains and a SEA (sea urchin sperm protein, enterokinase, and agrin) domain C-terminal to the PTS domain, thus they are classified as SEA-type mucins [17-26]. The 110-residue SEA domain is autocatalytically cleaved in an intramolecular strain-dependent process taking place in the endoplasmic reticulum [27-29]. The site of the autocatalytic cleavage is N-terminal to the serine residue in a G↓SVVV consensus motif found in the SEA domain (Fig. 2). The SEA cleavage of the single precursor protein results in a heterodimer which is held together via non-covalent interactions. Thus, SEA-type transmembrane mucins are presented as cleaved but yet associated heterodimers on the surface of cells.

A comparison between known SEA domain sequences reveals amino acid sequence differences between SEA domains in different SEA-type transmembrane mucins. MUC16, a transmembrane mucin originally identified as an ovarian cancer antigen, is the only transmembrane mucin with multiple SEA domains in tandem. All SEA domains on MUC16, with exception of possibly one, are incapable of strain-dependent cleavage due to the absence of the GSVVV consensus motif and the presence of a conserved pair of cysteines that stabilize an intramolecular disulfide bond between the  $\beta$ 2 and  $\beta$ 3 strands of the domain [30, 31]. Other SEA domains, e.g. domains found in MUC1, MUC3, MUC12, and MUC17, lack the particular cysteine pair in MUC16. Interestingly, the lack of a stabilizing cysteine pair correlates to the ability to undergo strain-dependent SEA cleavage. It has been suggested that transmembrane mucins harboring cleavable SEA domains are biologically destined to dissociate at the plasma membrane [28].

Unlike the SEA-type transmembrane mucins, MUC4 harbors two unique domains among membrane-tethered mucins; a nidogen homology region (NIDO) and the adhesion-associated domain in MUC4 and other proteins (AMOP) domain [21, 32]. In addition, MUC4

has a vWD domain. Consequently, MUC4 has been classified as a NIDO-AMOP-vWD-type mucin [26]. The vWD domain harbors a GD↓PH (glycine, asparagine, proline, and histidine) motif which has been proposed to be cleaved in the ER by a serine protease [33]. The GDPH motif is a feature shared with the secreted mucins MUC2

and MUC5AC, which instead undergo a pH-dependent autocatalytic cleavage in their GDPH motifs [34, 35].



**Fig. 2.** A schematic presentation of the SEA domain with its  $\alpha$ -helices and  $\beta$ -sheets. The SEA cleavage (G↓SVVV) site is marked with a black arrow.

### The transmembrane mucin MUC1

MUC1 is an extensively studied membrane-tethered mucin. It is assumed to be involved in tumor progression and immune activation. Along with MUC4 and MUC16, MUC1 is expressed on the surface of epithelial cells in the normal lung [36]. In addition to epithelial cells in the respiratory tract, MUC1 is expressed on apical surfaces of secretory epithelia and in a range of hematopoietic cells [3, 37]. The human *MUC1* gene is comprised of 7 exons which can be alternatively spliced to form transcripts from 3.7 to 6.4 kb, coding for a number of protein products. MUC1/SEC, lacking the type I transmembrane region,

is a secreted form of MUC1 [38]. The splice variants MUC1-CT80 and MUC1-CT58 differ from wild type MUC1 with regards to the length of their cytoplasmic tails (CTs) [39] and a fourth splice variant, MUC1/Y, lacks the extracellular glycosylated mucin domain [40].

The CT domain of MUC1 harbors several intracellular interaction and sorting motifs. MUC1CT interacts with various kinases, such as c-Src, members of the epidermal growth factor receptor (EGFR or ErbB) family, protein kinase C  $\delta$  (PKC $\delta$ ) and glycogen synthase kinase 3 $\beta$  (GSK3 $\beta$ ) [41-45]. Other binding partners of MUC1CT are  $\beta$ -catenin and the tumor repressor p53, regulating transcriptional events [46-48].

### **The intestinal transmembrane mucins MUC3, MUC12, and MUC17**

The membrane-tethered mucins MUC3, MUC12, and MUC17 are mainly found in the gastrointestinal tract. MUC3 is found in the intestine, colon and the gall bladder [49-51], MUC12 is expressed in the colon [20], while MUC17 is expressed throughout the intestinal tract, reaching an expression maximum in the duodenum [24]. The intestinal membrane-tethered mucins are genomically clustered on chromosome 7q22. Each of them is coded by 10 exons and they share similarities regarding exon-intron positions [2]. The signal sequence is coded by exon 1 and the first EGF-like domain is encoded by exon3 after exon 2 coding for the PTS domain. The SEA domain is coded by the third, fourth and fifth exons, while the second EGF-like domain is encoded by exons 6 and 7. The transmembrane domain lays in exon 7 followed by the cytoplasmic tail encoded by exons 7 to 10. It has been suggested that two forms of MUC3 coded by two distinct genes, *MUC3A* and

*MUC3B*, exist as a result of a recent gene duplication [50]. *MUC3B* displays amino acid changes in the end of the PTS domain. However, it is likely that the discovery of two forms of *MUC3* is attributed to single nucleotide polymorphism in the single *MUC3* gene.

The corresponding genomic region of intestinal membrane-tethered mucins expressed in the mouse is chromosome 5, locus qG2. The first SEA domain identified in the mouse genome was mapped to this chromosome region in the vicinity of the *Trim56* gene, a feature that is shared with the human *MUC17* gene which is found near the human *TRIM56* [2]. Despite the fact that the mouse mucin in this region has been annotated as *Muc3*, it is more likely that this protein is the mouse *MUC17* orthologue and therefore designated murine *Muc3(17)* [52]. The murine orthologues of the remaining two human transmembrane mucins expressed in the intestine, *Muc3* and *Muc12*, are not fully sequenced, thus rendering difficulties when studying the features and functions of these mucins in the mouse.

The major function of the intestinal transmembrane mucins is still an enigma. There are reports of increased amounts of *Muc3(17)* in a cystic fibrosis model in mice [39, 52, 53]. Endogenous human *MUC17* has been shown to promote cell migration and suppress apoptosis in colonic cell cultures. The underlying mechanism is dependent on ERK phosphorylation stimulated by EGF-like domains on *MUC17* [54]. Other studies indicate that suppression of *MUC17* in intestinal cell lines resulted in increased permeability and increased susceptibility to invasion by enteroinvasive *E. coli* [55]. These reports suggest that transmembrane mucins own cell-protective properties.

## PDZ adapter proteins

PDZ domains, originally identified in Post synaptic density protein 95, Drosophila disc large tumor suppressor, and Zonula occludens-1 protein, are the most common protein interaction domains in the metazoan [56]. In the human genome, over 1,100 PDZ domains have been identified in over 500 proteins, whereas the mouse genome contains over 700 PDZ domains belonging to more than 300 proteins [57, 58]. PDZ domains consist of 80-100 amino acids long single or repeated sequences sharing sequence homology across multiple species [59]. Their key function is the ability to bind ligands harboring C-terminal PDZ binding motifs (Table I). The first identified interaction between a PDZ protein and its ligand was binding of two N-terminal PDZ domains of PSD-95 to the specific C-terminal peptide motif (-E-T/S-D/E-V) of Shaker-type K<sup>+</sup> channels [60] and the NR2

**Table I.** A list of known ligands for three important Class I PDZ adaptor proteins.

| Ligand protein | PDZ adaptor protien | Effect of interaction                    | Reference  |
|----------------|---------------------|--|------------|
| BCR            | PDZK1               | Stabilization                            | 72         |
| NHE3           |                     | Signaling, activation                    | 73         |
| CFTR           |                     | Stabilization                            | 74, 75     |
| MRP2           |                     | Sorting and/or stabilization             | 65         |
| DRA            |                     | Signaling                                | 76         |
| SR-BI          |                     | Signaling                                | 77         |
| OAT4           |                     | Sorting and/or stabilization, activation | 78         |
| $\beta_2$ - AR | NHERF1              | Sorting and/or stabilization             | 79         |
| NHE3           |                     | Stabilization, activation                | 80         |
| CFTR           |                     | Sorting and/or stabilization, activation | 81, 82, 83 |
| iNOS           |                     | Sorting, activation                      | 84         |
| PDZK1          |                     | Stabilization, activation                | 85, 86     |
| CFTR           | GOPC                | Sorting                                  | 87         |



subunit of the NMDA receptor [61, 62]. These findings revealed that PDZ domains function as modular units and their C-terminal binding ability can be acquired when transferred to other heterologous proteins.


A single PDZ domain consists of six antiparallel  $\beta$ -strands ( $\beta$ A-F) organized in a sandwich and flanked by two  $\alpha$ -helices ( $\alpha$ A and  $\alpha$ B). The  $\beta$ B strand and the  $\alpha$ B helix are arranged into a groove which acts as a binding pocket for internal or C-terminal peptide motifs by entrapment of a free carboxylate group at the end of the ligand peptide. The loop responsible for binding of the carboxylate group lies between the  $\beta$ A and  $\beta$ B strands and the interaction between the carboxylate-binding loop and the carboxylate oxygen is necessary for the PDZ recognition of C-terminal peptides of the ligand. [43, 63]. The amino acid sequence for the carboxylate-binding loop (R/K-XXX-GLGF where X represents any amino acid) is therefore highly conserved among PDZ domains [64, 65].

The specificity and affinity of PDZ domains for corresponding C-terminal PDZ ligands has been readily studied. C-terminal amino acid motifs of PDZ ligands can be categorized into three distinct classes based on amino acid sequences from position 0 to position -2 on the ligand protein [66]. The first class of C-terminal PDZ motifs, designated Class I PDZ motifs, involves a hydrophobic amino acid residue on position 0 and serine or a threonine amino acid residue on position -2. The side chain hydroxyl group on the Ser or Thr amino acids forms a hydrogen bond with N-3 nitrogen present on a highly conserved histidine in position  $\alpha$ B1 [63]. The second class of PDZ motifs, Class II PDZ motifs, have hydrophobic residues at both position -2 of the peptide ligand and the  $\alpha$ B1 position of the PDZ domain [66]. Finally, a third class of PDZ motifs, Class III PDZ motifs, requires a negatively charged amino acid residue at position -2 on the peptide

ligand and a tyrosine at  $\alpha$ B1 position on the PDZ domain [67]. Despite a rigid classification of C-terminal PDZ motifs, several reports indicate that while residues at the positions 0 and -2 are important for PDZ interactions, more N-terminal sequences in the peptide ligands also contribute to specificity of the binding. For example, the amino acid at position -3 has also been reported to be in contact with the peptide-binding groove of the PDZ domain [63, 68, 69]. In fact, residues as far as position -8 have been reported to modulate the specificity of PDZ interactions [66, 70, 71].

### The ion channels of the small intestine

The small intestine is a highly specialized organ dedicated to digestion and absorption. It is lined with goblet cells that produce, store and discharge mucus, and with epithelial cells, that participate in absorption, ion exchange and hormonal activities [88, 89]. The absorptive enterocytes are polarized, columnar cells with distinct apical and basolateral domains that are separated



**Fig. 3.** A summary of secretory and absorptive ion channels present on the apical and basolateral membranes of an enterocyte in the small intestine.

by tight junctions. Each membrane domain possesses separate populations of proteins that require specific protein sorting machineries [86].

The small intestine coordinates transport of the major ions,  $\text{Na}^+$ ,  $\text{Cl}^-$ ,  $\text{K}^+$  and  $\text{HCO}_3^-$ , and combines ion transport with solute transport in order to move fluid across membranes (Fig. 3) [90]. Three channels are the major players involved in  $\text{Cl}^-$  secretion; the Cystic fibrosis transmembrane conductance regulator (CFTR), calcium-activated chloride channels (CaCC); and chloride channel type-2 (ClC-2) channels. A requirement for apical chloride secretion is the basolateral  $\text{Na}^+\text{-K}^+\text{-ATPase}$ . Driven by ATP, this channel transports three  $\text{Na}^+$  ions out of the cell while two  $\text{K}^+$  ions are carried into the cell [91, 92]. Chloride secretion is also dependent on the basolateral  $\text{Na}^+\text{-K}^+\text{-2Cl}^-$  cotransporter 1 (NKCC1) which mediates  $\text{Cl}^-$  uptake at the basolateral membranes of enterocytes [93, 94]. In addition to NKCC1, the basolateral membrane is the site of expression for potassium channels which through  $\text{K}^+$  efflux maintain intracellular electroneutrality and enable apical  $\text{Cl}^-$  secretion [95].

### **Cystic Fibrosis and the CFTR anion channel**

The *CFTR* gene, coding a protein belonging to the ATP-binding cassette (ABC) sub-family C of transporters, was identified in 1989 [96, 97]. ABC transporters constitute the largest family of transporters identified [98]. 48 ABC transporters have been identified in the human genome, all sharing the presence of two homologous nucleotide-binding domains as a common feature [99]. The CFTR ion channel consists of two six membrane-spanning domains (MSDs) and two nucleotide-binding domains (NBD) of which the first is flanked by the transmembrane domains and a regulatory (R) domain. The second NBD is located intracellularly C-terminal of the second transmembrane

domain. Finally, an intracellular C-terminal end domain contains a Class I PDZ binding motif [100].

CFTR differs from other members of the ABC transporter family by acting as an ion channel. Its function can be regulated by conformational changes in the two NBDs and modulation of the R domain which upon phosphorylation by protein kinase A (PKA) or C (PKC) increases channel opening. The probability of an actively gating or a quiet channel is therefore dependent on, and regulated by, the balance between kinases and phosphatases acting on multiple sites on the R domain [101].

CFTR mediates movement of chloride ions in order to enable the secretion and absorption of salts across the epithelial barrier [102]. Furthermore, it has long been known that CFTR is important for secretion of  $\text{HCO}_3^-$  and stimulation of  $\text{Cl}^-/\text{HCO}_3^-$  exchangers [103, 104]. It has also been postulated that CFTR regulates other ion channels such as epithelial sodium channel (ENaC) and the outwardly rectifying chloride channel (ORCC) [105, 106].

Mutations in the *CFTR* gene cause cystic fibrosis (CF), an autosomal recessive genetic disorder affecting organs such as the lung, pancreas, small intestine and sweat glands. The disease is characterized by impaired chloride and bicarbonate conductance across the apical surface of epithelial cells in the affected organs, resulting in a dehydrated mucus barrier which serves as habitat for pathogens that cause infections [107]. Up to date nearly 1.500 different mutations have been mapped to the *CFTR* gene. Although the majority of these mutations are associated with disease,  $\Delta\text{F508}$ , a single codon deletion of the amino acid phenylalanine at position 508, is the most common mutation on the *CFTR* gene. This mutation accounts for approximately 90% of CF cases in certain populations. The  $\Delta\text{F508}$  mutation results in incorrect folding of the CFTR protein, followed by retention

of the defective protein in the endoplasmic reticulum [108, 109]. The immature CFTR protein is then trapped by chaperones and degraded by cytosolic proteasomes [110, 111]. In the context of CF, the impaired efflux of  $\text{HCO}_3^-$  in response to either forskolin or carbachol results in decreased alkalization of the lumen, followed by hyperviscosity of secreted mucins due to altered processing [41].

### **$\text{Na}^+/\text{H}^+$ Exchanger 3, an absorptive ion channel**

$\text{Na}^+/\text{H}^+$  exchange is the means by which  $\text{Na}^+$  is absorbed across epithelia. The first evidence of sodium and hydrogen transport across brush border membranes of epithelial cells in the intestine was presented nearly forty years ago [112]. The discovery proved that protons were moved out across brush border membranes when sodium was added to the luminal side of cells, thus acidifying the extracellular medium, and that the  $\text{Na}^+$  influx and  $\text{H}^+$  efflux with the stoichiometric ratio 1:1, was mediated through an antiport mechanism. A gene encoding the first member of the  $\text{Na}^+/\text{H}^+$  exchanger was cloned in 1989 [113].  $\text{Na}^+/\text{H}^+$  exchangers are expressed in every cell type in eukaryotes and their primary function is to regulate intracellular pH, cell volume and proliferation, and to mediate transepithelial absorption of  $\text{Na}^+$  [114, 115]. In the human,  $\text{Na}^+/\text{H}^+$  exchanger 3 (NHE3) is expressed primarily in kidneys, small intestine and colon [8]. It is expressed in the brush border membrane of renal proximal tubule cells and in the brush border of epithelial cells lining intestinal villi and to a lesser extent in epithelial cells of the crypts [116, 117]. Similar to other members of  $\text{Na}^+/\text{H}^+$  exchangers, NHE3 has a N-terminal part, consisting of 11 membrane-spanning  $\alpha$ -helices [118]. This N-terminal part is necessary for  $\text{Na}^+/\text{H}^+$  exchange, whereas the C-terminal domain mediates calmodulin-dependent inhibition of basal activity and

regulatory inhibition via PKC phosphorylation [119, 120]. In addition, the C-terminal domain harbors growth factor-mediated stimulatory sites [119]. Membrane-tethered NHE3 is linked to the underlying cytoskeleton via a direct interaction mediated by an internal ezrin-binding site on the C-terminus of the transporter. The C-terminus contains an additional internal site for PDZ-binding to NHERF1 and NHERF2 [13, 15, 16]. Finally, NHE3 has a Class I PDZ binding motif for PDZK1 on its far C-terminus [121].

### **Carbachol, a cholinergic agonist**

The human intestinal tract secretes approximately 8 liters of fluid during a 24-hour period. In normal conditions the major part of this volume is absorbed during transition through the small and large intestine, reaching maximum fluid absorption in distal parts [93]. Chloride secretion from enterocytes is induced by secondary messengers, i.e. cAMP and cGMP and  $[Ca^{2+}]_i$  [93]. Moreover, hormones such as Prostaglandin  $E_1$  ( $PGE_1$ ) and Vasoactive intestinal polypeptide (VIP) are involved in  $Cl^-$  secretion by increasing levels of cAMP [122]. Specifically, cAMP induces PKA-mediated phosphorylation of CFTR, thus generating  $Cl^-$  secretion. Increased levels of either cAMP or cGMP result in inhibited  $Na^+$  and  $Cl^-$  absorption [123, 124].

Acetylcholine, an organic neurotransmitter, has been shown to induce  $Cl^-$  secretion by elevating levels of  $[Ca^{2+}]_i$ . Studies on cultures of colonic or intestinal-like cells lines lacking neuronal features, have revealed that the action of analogues of acetylcholine, i.e. carbachol, on the intestinal epithelium is direct [125]. In cell cultures, carbachol acts in a dose-dependent manner and generates a transient change in the short circuit current ( $I_{sc}$ ), lasting approximately 10 min. This is accompanied by an equally transient increase in  $Cl^-$  secretion. However, isolated

intestinal tissue contains other secretagogues, such as  $\text{PGE}_1$  and VIP, resulting in a more sustained change in  $I_{sc}$  [125]. Mitochondria, ER, calmodulin and basolateral  $\text{Ca}^{2+}$  and  $\text{Na}^+$  channels are all involved in mobilization of  $[\text{Ca}^{2+}]_i$  [126].


In the duodenum, secretion of  $\text{HCO}_3^-$  via CFTR is stimulated by elevated cAMP as a result of forskolin. Carbachol stimulation, i.e. elevated  $[\text{Ca}^{2+}]_i$ , also generates  $\text{HCO}_3^-$  secretion [127, 128]. In fact, it has been shown that carbachol stimulates Cftr exocytosis at the brush border membrane (BBM) in the small intestine of wild-type rats. NHE3 regulation occurs in both physiological and pathological conditions. For example, extensive loss of water via secretion and impaired NHE3-mediated absorption during diarrhea in response to bacterial toxins, are caused by elevation of second messengers such as cAMP, cGMP, and  $[\text{Ca}^{2+}]_i$  [129]. In fact, elevation of  $[\text{Ca}^{2+}]_i$  via carbachol or ionomycin, inhibits NHE3 due to increasing endocytosis, followed by formation of intracellular multiprotein complexes containing NHE3 [21, 130-134]. It has been shown that acute  $[\text{Ca}^{2+}]_i$ -mediated regulation of NHE3 in the plasma membrane is dependent on PDZ adaptor proteins belonging to the NHERF family [129, 133]. However tissue-dependent, generally NHERF1 is involved in cAMP-mediated inhibition of NHE3, whereas  $[\text{Ca}^{2+}]_i$ -mediated inhibition of NHE3 is dependent on NHERF2 [135]. PDZK1 (NHERF3) mediates both cAMP- and  $[\text{Ca}^{2+}]_i$ -dependent inhibition of NHE3 [136, 137]. While NHERF4 facilitates exocytosis and increased NHE3 activity in response to elevated  $[\text{Ca}^{2+}]_i$  [138].

Several studies have revealed that CFTR possesses the ability to influence NHE3 and several mechanisms have been suggested. One report has shown that CFTR mediates forskolin-induced elevation of  $[\text{Ca}^{2+}]_i$ , thus potentially affecting NHE3 distribution and activity

[139]. In another study, it was shown that forskolin-induced activation of CFTR amplifies inhibition of NHE3 via cAMP. Data from mouse pancreas and fibroblast expressing both CFTR and NHE3 heterologously reveal that NHERF1 crosslinks CFTR and NHE3 [140].

### The brush border of enterocytes

The apical domain of enterocytes is characterized by a brush border consisting of a dense array of microvilli protruding from the cell surface. Approximately 1,000 microvilli extend out from each cell, generating a 30-fold increase in cell surface area and allowing efficient exchange with the extracellular milieu [141, 142]. The brush border consists of a BBM covered by a dense glycocalyx and an underlying cytoskeletal structure. The glycocalyx is a thick filamentous coat covering



**Fig. 4.** A cartoon showing the arrangement of the apical brush border of epithelial cells. The right panel displays the organization of the terminal web and the microvilli. The left panel shows the connections between a membrane-tethered ion channel and F-actin via the PDZ protein NHERF1 and the F-actin-binding protein Ezrin. NHERF1 is also able to anchor additional PDZ adaptor proteins, e.g. PDZK1, which in turn can bind membrane-anchored proteins.



the microvilli of enterocytes (see Fig. 1) [44]. Initially termed as the fuzz, this thick layer reacts with periodic acid-Schiff stain, demonstrating the existence of glycoproteins and glycolipids. Moreover, positive staining with Alcian blue points toward the presence of sulfated and carboxylated glycoproteins in the glycocalyx [58]. Long stretched transmembrane mucins reaching approximately 1  $\mu\text{m}$  in length, are the only known proteins expressed on apical surfaces which could explain the characteristic filamentous appearance of the glycocalyx. Although existing data indicate that heavily glycosylated transmembrane mucins make up the major part of the glycocalyx covering intestinal cells, tangible proof is still lacking.

The underlying cytoskeletal structure that is required for the ordered arrangement and dynamics of the BB is composed of vertical filamentous actin (F-actin) along the length of the microvillar region and horizontal F-actin in the terminal web region situated under the base of microvilli (Fig. 4). Other protein components are responsible for crosslinking of actin filaments in both regions. Briefly, F-actin serves as a core bundle in the microvilli. In turn, F-actin is cross-linked by fimbrin and villin [143, 144]. The cross-linked F-actin core bundle is radially attached to the adjacent microvillar membrane through ATP- and calcium-sensitive myosin1A-calmodulin-complexes [145, 146]. This complex mediates apical membrane migration along actin filaments towards the tip of microvilli and has been suggested to promote shedding of vesicles from BBM [147].

### **Vesicle trafficking in polarized epithelial cells**

Polarized epithelial cells display conserved features in different organs. They are characterized by their organization into tight monolayers of cells, acting as boundaries between internal compartments and

the extracellular milieu. The specialized functions of epithelial cells require: 1) separated apical and basolateral membrane domains, 2) distinct populations of membrane proteins at each membrane domain, and 3) a polarized sorting machinery that targets different membrane proteins to the apical and basolateral domains [148]. The major site for intracellular sorting of various membrane proteins is the outermost cisterna of the Golgi apparatus, namely the *trans*-Golgi network (TGN) [101]. Here, at least two sorting pathways for exocytosis, a lipid raft-dependent pathway and a galectin-dependent pathway, are at play [149-153]. Furthermore, sorting signals on cargo proteins destined to be presented on apical or basolateral membrane surfaces are responsible for polarized transport from the TGN to the two distinct plasma membrane domains. Apical sorting signals include ectodomain signals such as *N*- and *O*-glycans, glycosylphosphatidylinositol (GPI) anchors, and cytoplasmic signals [154-157]. Basolateral sorting signals, mainly cytoplasmic tyrosine together with hydrophobic residues, or dileucine motifs, are identified by adaptor complexes (APs) that together with clathrin form clathrin-coated vesicles, that enclose the cargo during transport from the TGN to basolateral membranes and endosomal compartments [158-162].

Another trafficking route characteristic for specialized secretory cells, such as goblet cells, is the regulated secretory pathway. This pathway involves synthesis, modification, sorting, storage, and controlled release of secretory proteins such as secreted mucins from the cell. In detail, translated secretory mucins undergo folding, assembly and glycosylation in the ER [163, 164]. Proteins are then transported to the Golgi apparatus, where they undergo further processing and maturation [59]. Synthesized mucins are then sorted in the *trans*-Golgi network and stored in regulated secretory vesicles that await secretory stimuli prior to discharge from the cell

[165]. The packing of mucins in these vesicles requires acidic pH as well as high concentrations of calcium [166-168]. These conditions trigger the aggregation of the N-terminal end of the mucin and a well-organized packing which allows release and expansion without entanglement [169]. Both microtubules and actin filaments are involved in the transport of secretory granules to the plasma membrane, where cargo is emptied in the lumen upon membrane-tethering, docking and fusion [170, 171].

In analogy with exocytosis, endocytosis in epithelial cells occurs in a polarized fashion, involving functionally and physically specialized compartments. Two major types of endocytic routes have been described: 1) clathrin-mediated endocytosis (CME) involving clathrin, AP-2 and dynamin, and 2) lipid raft-dependent endocytosis facilitated by caveolae, which are vesicles rich in cholesterol and caveolin 1 [172-175]. Membrane proteins are targeted for CME when cytoplasmic conserved motifs, containing tyrosines and amino acids with large hydrophobic side chains, are identified by AP2 [176, 177]. AP2 also provides binding sites for clathrin, thus mobilizing clathrin which in turn induces membrane curvature and vesicle budding mediated by the GTPase dynamin [178, 179]. Endocytosed vesicles carrying cargo membrane proteins are then sorted in endosomes. Firstly, incoming endocytosed cargo reaches slightly acidic early endosomes (EE), where sorting occurs [180, 181]. Secondly, the cargo reaches recycling endosomes (RE) via a geometric transition of EEs. REs containing cargo are either recycled to the plasma membrane or translocated to the perinuclear cytoplasm, where they congregate in close association with microtubule organizing centers (MTOC) [182-184]. Perinuclear REs, which contain an intracellular pool of recycling cargo, can in turn be remobilized to the plasma membrane to release their cargo. For example, up to 75%

of expressed transferrin receptors reside in perinuclear REs, awaiting recycling to the plasma membrane [185]. Another transport passage for cargo residing in EEs is along microtubules destined for late endosomes (LEs). LEs contain lysosomal enzymes, e.g. hydrolase, which degrade internalized content. Finally, internalized cargo is accumulated in lysosomes.

### **Trafficking of membrane-tethered mucins**

While the mechanism behind trafficking of intestinal membrane-tethered mucins remains to be fully elucidated, data from studies on the membrane mucin MUC1 reveal a complex endocytic machinery and regulated sorting in different endosomal vesicle populations. It has been shown that *N*-glycans in the vicinity of the MUC1 transmembrane domain are necessary for apical targeting of the membrane mucin [186]. Also, endocytosis of MUC1 depends on the extent of *O*-glycosylation of the mucin domain, as mucin with less *O*-glycosylation undergoes faster endocytosis [187]. Others studies have shown that EGF-stimulation induces internalization of MUC1CT via CME followed by fusion of endocytic vesicles with Rab5-positive vesicles in the early endosome [188]. The complex mechanism behind MUC1 internalization becomes evident when taking into account the requirement of cytoplasmic tyrosine residues for endocytosis via binding to AP-2 and growth factor receptor-bound protein 2 (Grb2) [189]. The subsequent recycling of MUC1 is regulated by post-translational transmembrane *S*-palmitoylation. Blocked *S*-palmitoylation results in decreased recycling of MUC1 to the cell surface and accumulation in recycling endosomes [190].

### **Trafficking of CFTR and NHE3**

Biosynthesis, exocytosis, and endocytosis of CFTR are subjected to extensive regulation. In the ER, CFTR undergoes folding and a quality control machinery targets misfolded proteins for ubiquitination and degradation via ER-associated degradation (ERAD) [191, 192]. Further processing of correctly folded protein takes place in the Golgi apparatus where mannose sugars, present on the fourth extracellular loop of CFTR, are converted to complex oligosaccharides [17, 191]. From the Golgi, CFTR is transported in clathrin-coated vesicles to the apical surface of the cell, where the ion channel undertakes anion secretion. CFTR displays rapid turnover due to extensive endocytosis and recycling [17, 193]. It has been shown that endocytosis of CFTR is clathrin-dependent and that the internalized anion channel travels via EEs to REs while some fractions continue to the lysosomes for degradation [19, 108]. Interestingly, a major fraction of mature CFTR undergoes degradation in lysosomes via LEs. In fact, only 5 to 15% of mature and functional CFTR needs to be apically expressed for proper intestinal anion secretion [25, 194].

In contrast to CFTR, basal endocytosis of a fraction of NHE3 is dependent on formation of discrete lipid raft membrane domains [195]. However, reports of CME of NHE3 suggest different endocytic mechanisms involved in basal and stimulated endocytosis of the exchanger [196]. The localization of NHE3 in BBM of polarized cells is regulated by alterations in  $[Ca^{2+}]_i$  [21, 138]. Stimulation of intestinal enterocytes with carbachol, that leads to elevated  $[Ca^{2+}]_p$ , has been reported to induce internalization of NHE3 into early endosomes [197].

In the context of ion channel trafficking, the role of PDZ adaptor proteins belonging to the NHERF family must be mentioned. Members of the NHERF family are not only involved in regulation of CFTR and NHE3 but

they also regulate targeting and retention of ion channels in different subcellular compartments. In *Nherf2* KO mice, the localization of Nhe3 was shifted from the apical surface to intracellular pools, thus resulting in decreased Nhe3 activity [135]. NHERF1 has been shown to link CFTR to Ezrin, thereby tethering the anion channel to the plasma membrane. Furthermore, it has been proven that the C-terminal PDZ motif of CFTR plays a role in recycling of endocytosed CFTR to the plasma membrane [198]. Golgi-associated PDZ and coiled-coil motif-containing protein (GOPC), a TGN-resident PDZ protein, is able to target CFTR to lysosomes for degradation, a mechanism that is bypassed by NHERF1 that redirects CFTR to apical membranes [87, 199, 200]. In summary, the distribution and activity of ion channels and exchangers is closely monitored and regulated by adaptor and scaffolding proteins associated with various subcellular compartments and organelles.

## **Aims of thesis**

---

The overall aim of the thesis work was to provide a deeper understanding of the function and regulation of intestinal SEA-type transmembrane mucins.

### **Specific aims**

1. To identify novel interactions between C-termini of transmembrane mucins and PDZ adaptor proteins.
2. To study the specific action of PDZ adaptor proteins on expression and subcellular localization of transmembrane mucins.
3. To study the relationship between transmembrane mucins and ion channels expressed in the small intestine.
4. To assess the magnitude of forces stabilizing the SEA domain of MUC1.

# Methods

# 2

## **Animals (Papers I and IV)**

All animal experiments were approved by the animal ethics committee at the University of Gothenburg. The *Pdzk1*<sup>-/-</sup> mice were generated in the Department of Pathology, Beth Israel Deaconess Medical Center [201]. *NHERF1*<sup>-/-</sup> mice, backcrossed for 8 generations into the FVB/n background, were generated from heterozygotes produced at the Duke University Medical Center [202]. *NHERF2*<sup>-/-</sup> mice, backcrossed for 14 generations into the FVB/n background, were produced from heterozygotes generated at the Erasmus University Medical Center [203]. C57/BL6 mice were used as wild-type controls.

## **Antibodies (Papers I, II, and IV)**

A number of raised antibodies against human and murine transmembrane mucins were used in the studies described in this thesis. Briefly, synthetic peptides against specific regions on the transmembrane mucin of interest were conjugated to KLH, purified and used for immunization of two rabbits. The polyclonal antibody (pAb) against murine Muc3(17) has previously been described [52]. An anti-MUC17S1 pAb was raised against the peptide LKNHSSQEFQEFKQTFTEQMNIC in a region N-terminal of the SEA cleavage site. Anti-MUC17S2 pAb was raised against the peptide KYTPEYKTVLDNATEVVKEKIKVC, targeting a region C-terminal of the SEA cleavage site. Anti-



MUC3C1 polyclonal antibody was raised against a CDTTMKVHIKRPEMT peptide on the C-terminal tail of human MUC3.

### **Atomic force microscopy (Paper III)**

Atomic force microscopy was used for force measurements on a recombinant protein, containing three MUC1-derived SEA domains, at  $23 \pm 0.5^\circ\text{C}$  using PicoScan software (version 5.3.3; Molecular Imaging) together with a PicoSPM atomic force microscope (Molecular Imaging). The recombinant protein was immobilized on mica sheets coated with a 5 nm thick chromium adhesion layer and a 25 nm thick gold layer. Double-side gold-coated CSC38/Cr-Au cantilevers chips ( $k_{\text{spec}} = 0.03 \text{ N/m}$ ) were coated with thiolated-NTA (HS(CH<sub>2</sub>)<sub>11</sub>-EG3-NTA in ethanol). The approach/retraction speed for all experiments was  $v \approx 820 \text{ nms}^{-1}$  (loading rate  $vk \approx 25 \text{ nNs}^{-1}$ ).

### **Labeling of surface glycoproteins (Paper IV)**

Surface glycoproteins, presented on the surface of polarized Caco-2 cells, were labeled using biotin-hydrazide after oxidation of carbohydrate moieties with sodium *meta*-periodate. The method was first described by O'Shannessy *et al.* [204]. Labeled surface glycoproteins were then extracted by subsequent clearance of cell lysates, removal of free biotin-hydrazide and affinity precipitation using streptavidin conjugated to magnetic beads.

# Results

# 3

## Transmembrane mucins are ligands for PDZ adaptor proteins (Paper I and II)

There is limited knowledge regarding the function of the three transmembrane mucins, MUC3, MUC12, and MUC17, expressed in the human small intestine. While the domain structure of these SEA mucins has been determined, as described in Chapter 1, the cytoplasmic tails of MUC3, MUC12, and MUC17 have not been assigned any specific features or functions. As a first measure, we set out to identify consensus sequences in the intracellular C-termini of each of the three transmembrane mucins. Using the Eukaryote Linear Motif resource, we identified a four amino acid residue consensus sequence classified as a Class I PDZ motif in the far C-termini of MUC3, MUC12, and MUC17 (see Fig. 5) [205]. A Class I PDZ motif is characterized by the consensus sequence X-[S/T]-X-Φ, where X represents any amino acid and Φ represents a hydrophobic amino acid.

| Mucin   | Position | -50                  | -40                 | -30                | -20         | -10         | -2 | 0 |
|---------|----------|----------------------|---------------------|--------------------|-------------|-------------|----|---|
| MUC3CT  |          | -QDRKWFETWDEEVVGTFSN | WGFEDDGTDKDTNFHVALE | NVDTTMKVHIKRPEMT   | <b>SSSV</b> |             |    |   |
| MUC12CT |          | -KEGTPGIFQKTAIWEDQNL | RESRFGLE            | NAYNNFRPTLETVDSGTE | LHIQRPEMV   | <b>ASTV</b> |    |   |
| MUC17CT |          | -EDSGPAPGTFQNI       | GFDICQDDSIHLESIYS   | SNFQPSLRHIDPETKIRI | QRPQVM      | <b>TTSF</b> |    |   |

**Fig. 5.** Class I PDZ motifs (bold letters) in the far C-termini of transmembrane mucins MUC3, MUC12, and MUC17.

### **MUC3 C-terminus binds Golgi-resident GOPC**

In order to screen the Class I PDZ motif of MUC3CT for binding to PDZ adaptor proteins, we used an array of 123 different immobilized human PDZ domains. MUC3CT was fused to Yellow Fluorescent protein (YFP) and analyzed with an overlay assay involving PDZ domain arrays. A strong binding to the Golgi-associated PDZ and coiled-coil motif containing protein, GOPC, was observed (Fig. 2A, Paper II). Interestingly, the YFP fusion protein of MUC12CT did not bind GOPC while YFP-MUC17CT displayed a weak interaction. Although the Class I PDZ motif is a shared feature amongst MUC3, MUC12, and MUC17, only MUC3 exhibited high binding specificity for GOPC (Fig. 2B, Paper II). In order to assure that the MUC3CT-GOPC-interaction was PDZ mediated, the Class I PDZ motif on MUC3CT was removed. This inhibited the binding to GOPC (Fig. 2C, Paper II).

### **MUC17 C-terminus binds scaffolding protein PDZK1**

Similarly, MUC17CT was screened for binding to PDZ adaptor proteins. MUC17CT displayed a strong interaction for the second PDZ domain of PDZK1 (PDZK1-D2) (Fig. 1B, Paper I). Next, MUC17CT fused to Glutathione S-Transferase (GST) was used as a bait in lysates from the colonic adenocarcinoma cell line, HT29. Compared to GST, GST-MUC3CT, and GST-MUC12CT that did not bind any PDZ adaptor proteins, GST-MUC17CT interacted with endogenous PDZK1 in HT29 lysates (Fig. 1C, Paper I). The specificity of MUC17CT for PDZK1 was shown to be PDZ-dependent as truncated MUC17CT, lacking the Class I PDZ motif, did not bind PDZK1 (Fig. 2B, Paper I). Finally, we demonstrated that the first, second and fourth PDZ domains of PDZK1 exhibited the ability to bind the specific Class I PDZ motif present on MUC17CT (Fig. 2C, Paper I).

### **PDZK1 anchors MUC17 to apical membranes of enterocytes (Paper I)**

The murine orthologue of human MUC17 is designated Muc3(17). In analogy to MUC17, the C-terminus of Muc3(17) contains a Class I PDZ motif consisting of the amino acid sequence MTSL (L at position 0). We tested whether Muc3(17)CT was able to bind murine Pdzk1 in lysates from mouse jejunum. Indeed, GST-Muc3(17)CT bound Pdzk1. Interestingly, Pdzk1 was also able to bind human MUC17, suggesting a conserved functional interaction between PDZK1/Pdzk1 and MUC17/Muc3(17) across the human and the mouse, despite the differences in their PDZ-binding motifs (Fig. 3, Paper I). Next, the expression and subapical localization of Muc3(17) was analyzed in jejunal sections of wild-type (Wt) and Pdzk1<sup>-/-</sup> mice. In Wt mice, Muc3(17) was localized to the outer part of the apical brush border of enterocytes while in Pdzk1<sup>-/-</sup>, Muc3(17) was localized in intracellular vesicles, with a local accumulation in the subapical region below the apical plasma membrane (Fig. 4 A-C, Paper II). Thus, we concluded that Pdzk1 was important for membrane-tethering of Muc3(17).

### **Transmembrane mucins and ion channels are co-regulated (Paper II and IV)**

Having identified PDZ proteins as binding partners for the transmembrane mucins MUC3 and MUC17, we turned our attention to the functional aspects of these novel PDZ-mediated interactions.

#### **MUC3 interacts and colocalizes with GOPC**

Our previous *in vitro* data suggesting a binding between MUC3CT and GOPC were tested in the BHK 21 cell line. A recombinant protein consisting of MUC3CT fused to the transmembrane and SEA domains of MUC17 (Myc-MUC17/MUC3CT) was stably expressed

in BHK 21 cells. Likewise, the same protein lacking the last six amino acid residues and thus the Class I PDZ motif of MUC3CT, was stably expressed in BHK 21 cells. GOPC was fused to a hemagglutinin (HA) tag and overexpressed in the two stable cell lines. Myc-MUC17/MUC3CT colocalized with GOPC whereas Myc-MUC17/MUC3CT $\Delta$ 6 did not (Fig. 3 B-D, Paper II). Co-immunoprecipitation experiments validated these results as Myc-MUC17/MUC3CT precipitated HA-GOPC while Myc-MUC17/MUC3CT $\Delta$ 6 only bound very weakly to HA-GOPC. These results were reproduced in a reciprocal co-immunoprecipitation experiment where HA-GOPC was used as bait (Fig 4, Paper II).

### **GOPC suppresses total levels of MUC3 but does not affect membrane-tethered MUC3**

Published data suggest that GOPC entraps CFTR in the *trans*-Golgi network and targets the ion channel to the lysosomes for degradation [87, 199, 200, 206]. We tested whether GOPC possessed the ability to suppress total protein levels of MUC3. Indeed, overexpression of HA-GOPC resulted in decreased total levels of Myc-MUC17/MUC3CT, whereas HA-GOPC did not suppress Myc-MUC17/MUC3CT $\Delta$ 6 (Fig. 5B, Paper II). Using fluorescent-associated cell sorting (FACS) the effect of HA-GOPC on total and membrane-anchored Myc-MUC17/MUC3CT was assessed. Similar to the results from western blot analysis, total levels of Myc-MUC17/MUC3CT were decreased in presence of HA-GOPC (Fig. 5D, Paper II). However, we did not observe any significant decrease in surface levels of Myc-MUC17/MUC3CT upon introduction of HA-GOPC (Fig. 5C, Paper II). We also observed increased total levels of Myc-MUC17/MUC3CT $\Delta$ 6 in mock-transfected cells compared to Myc-MUC17/MUC3CT

in mock-transfected cells. A possible explanation for this is that recombinant MUC3 lacking the Class I PDZ motif bypasses GOPC-mediated lysosomal degradation, thus resulting in higher overall levels of the truncated protein in comparison to MUC3 with an intact Class I PDZ motif.


### **CFTR counteracts the down-regulatory action of GOPC on MUC3**

At this point, we had identified GOPC as a shared PDZ binding protein for MUC3 and CFTR. We had also shown that GOPC suppressed the total protein levels of both the transmembrane mucin and the anion channel. Consequently, we postulated that MUC3 and CFTR coexisted in late Golgi and competed for binding to the single PDZ domain present on GOPC proteins. To test this hypothesis, increased amounts of CFTR were introduced in BHK 21 cells stably expressing Myc-MUC17/MUC3CT. With increasing amounts of CFTR, the total levels of Myc-MUC17/MUC3CT increased correspondingly. This effect was not observed in Myc-MUC17/MUC3CT $\Delta$ 6 (Fig. 6, Paper II). Next, we turned to Caco-2 cells which express both endogenous MUC3 and CFTR. Firstly, YFP-MUC3CT or YFP-MUC3CT $\Delta$ 6 was introduced into Caco-2 cells and the overall levels of CFTR were assessed using FACS. Overexpression of YFP-MUC3CT resulted in a 20% increase in total levels of endogenous CFTR (Fig. 7A, Paper II). In contrast, introduction of YFP-MUC3CT $\Delta$ 6 did not alter CFTR levels. Secondly, increasing amounts of the cytoplasmic tail of CFTR (YFP-CFTR1440-80) were introduced into Caco-2 cells and total protein expression of endogenous MUC3 was analyzed. Overall MUC3 levels were augmented with increasing amounts of YFP-CFTR1440-80 (Fig. 7B, Paper II). These data suggested that CFTR can compete with MUC3 for binding to GOPC and that CFTR engaged free PDZ domains on

GOPC molecules, thus rescuing MUC3 from lysosomal degradation. Moreover, the reciprocal setup suggested that overexpression of MUC3 resulted in CFTR bypassing lysosome-mediated degradation, as summarized in our model (see Fig. 6).

**Apical MUC17 dissociates from PDZK1 and resides in early endosomes upon carbachol-mediated endocytosis**

The results obtained from our study of MUC3 indicated that transmembrane mucins can share cellular regulatory systems with ions channels that are important for cell homeostasis and mucus hydration. MUC17 is the major transmembrane mucin in the intestine and it reaches maximum transcript level in the duodenum, with a slight decrease in the ileum, followed by elevated



**Fig. 6.** A proposed model for the PDZ-mediated competition between MUC3 and CFTR for binding to GOPC in the *trans*-Golgi network.

numbers in the transverse colon and finally, slightly lower transcript levels in the descending colon and rectum [24]. Interestingly, the protein expression profile of MUC17 in the small and large intestine follows the distribution of CFTR and NHE3 ion channels [207, 208]. The scaffolding protein PDZK1 is involved in the correct subcellular localization of MUC17, CFTR, and NHE3 and moreover, PDZK1 is involved in the regulation of the two ion channels. As mentioned in Chapter 1, both CFTR and NHE3 are sensitive to carbachol (CCh) stimulation. In the case of NHE3, PDZK1-binding is abolished in response to CCh-induced elevation of  $[Ca^{2+}]_i$ , which results in NHE3 endocytosis. Consequently, we hypothesized that CCh could modulate MUC17 recruitment to the apical cell membrane of enterocytes. This hypothesis was tested in Caco-2 cells expressing endogenous MUC17 (Fig. 1A, Paper IV). Surface biotin-labeling of membrane-anchored MUC17 revealed that surface MUC17 was decreased upon CCh stimulation of Caco-2 cells (Fig. 1E-F, Paper IV). Interestingly, the dynamin-inhibitor Dynasore could inhibit the endocytosis of MUC17. This was in agreement with the existence of a putative AP-2 binding site on the MUC17CT. Confocal microscopy in untreated cells showed that MUC17 was expressed on the upper portion of the microvilli, separated from the dense F-actin staining defined as the boundary between the microvilli and the underlying terminal web. However, when cells were treated with CCh, MUC17 was internalized and redistributed to the F-actin stained region (Fig. 2A-B, Paper IV). A similar experiment performed on tissue from mouse duodenum, indicated that Muc3(17) was internalized upon CCh-treatment (Fig. 7, Paper IV). Colocalization studies showed that a majority of endocytosed MUC17 in CCh-stimulated cells was found in EEA1-positive early endosomes (Fig. 3, Paper IV). We also analyzed the expression and localization of



MUC17 in relation to the scaffolding protein, PDZK1. While MUC17 colocalized with PDZK1 under basal conditions, less colocalization was observed in CCh-treated cells, suggesting that CCh induces dissociation of MUC17 from PDZK1, and that this dissociation allows for endocytosis of the transmembrane mucin (Fig. 4, Paper IV).

### **Internalization of apical MUC17 is concomitant with NHE3 endocytosis and recruitment of CFTR to the apical surface**

Several studies point toward the role of CCh in distribution of NHE3 and CFTR in the apical brush border of enterocytes. Jakab *et al.* have reported that Nhe3 is endocytosed while Cfr is recruited to the apical surface when rat small intestine is stimulated with CCh [197] and Zachos *et al.* reported similar findings regarding NHE3 in Caco-2 cells [73]. Therefore, the distribution of MUC17 in the brush border of Caco-2 cells was studied in relation to NHE3. MUC17 and NHE3 were localized to the outer part of microvilli in untreated cells and both were endocytosed in presence of CCh (Fig. 5A-B, Paper IV). Similarly, we analyzed the distribution of MUC17 in relation to CFTR. Previous studies have shown that only a small fraction of CFTR is presented on the cell surface, while a major population is found intracellularly where CFTR undergoes quality control [25, 194]. Indeed, the strongest staining for CFTR was found below the terminal web region in Ctrl Caco-2 cells. Stimulation with CCh caused the redistribution of CFTR towards the apical surface (Fig 6, Paper IV). This suggested that CFTR is recruited to the lower part of the microvilli. We concluded that the internalization of MUC17 in response to CCh is concomitant with NHE3 endocytosis and CFTR recruitment to the apical surface of Caco-2 cells.

### **SEA-type transmembrane mucins act as protective devices (Paper III)**

The folding dynamics of the SEA domain has been readily studied. Macao *et al.* showed that the MUC1 SEA domain undergoes an autocatalytic strain-dependent cleavage during early biosynthesis in the ER [28]. They also suggested that the dissociation of the processed SEA domain is most likely mediated by mechanical forces. Still, only speculations exist regarding the actual function of this highly conserved domain.

### **The heterodimeric SEA domain of MUC1 is instable at elevated temperatures**


As a first measure, the stability of the MUC1 SEA domain was assessed. A recombinant protein harboring a SEA domain with a native cleavage site (LFRPG↓SVVV) and a recombinant protein with a non-cleavable SEA domain (LVPRGSVVV) were subjected to different temperatures. The cleavable SEA domain dissociated completely at 100°C and incomplete dissociation was observed at 80°C (Fig. 1C, Paper III). The native SEA domain was resistant to cleavage at 60°C. We concluded that the native SEA domain of MUC1 was stable at biologically relevant temperatures. So we turned our attention to mechanical forces that could dissociate the SEA domain.

### **A recombinant protein harboring three non-cleavable SEA domains in tandem unfolds in an ordered fashion**

Atomic force microscopy (AFM) is a widely applied technique for high-resolution scanning of surfaces. The technique is also used for force spectroscopy defined as the measurement of tip-specimen interaction forces. We brought this technique into play aiming at measuring forces required for dissociation of a single SEA domain. A recombinant protein was designed, composed of three identical MUC1 SEA domains, flanked by an N-terminal

12×Histidine (12×His)-tag and a C-terminal IgG2a-tag (See Figure 7). The cleavage site in each SEA domain was looped with four additional glycines (GGGGSVVV), rendering a non-cleavable site [28]. The AFM cantilever was functionalized with nitrilotriacetic acid (NTA), which forms coordination compounds with metal ions. In presence of  $\text{Ni}^{2+}$ , a His-NTA-complex connected the cantilever to the N-terminal 12×His-tag of the recombinant protein. The recombinant protein was immobilized on a gold surface via its C-terminus prior to binding to the cantilever. Pulling the cantilever at a loading rate of  $25 \text{ nNs}^{-1}$ , generated an average unfolding force of  $168 \pm 73 \text{ pN}$  for a single MUC1 SEA domain (Fig. 5, Paper III). A SEA domain consists of 104 amino acid residues, each with a persistence length of 0.4 nm. In other words, a fully stretched SEA domain measures approximately 42 nm. The obtained data indicated that the complete unfolding of a single SEA domain resulted in a contour length of  $32 \pm 7 \text{ nm}$  (Fig. 4, Paper III). When the distance between N- and C-terminal amino acids in the folded SEA domain (approximately 3.5 nm) is taken into account, the contour length obtained from our experiments is in good agreement with the theoretical length of a fully stretched out SEA domain.

**Figure 7.** A cartoon showing a recombinant protein, harboring three MUC1-derived SEA domains, flanked by a N-terminal 12×His-tag and a C-terminal IgG2a-tag.





# Discussion

# 4

This thesis explores the relationship between transmembrane mucins and ion channels important for cell homeostasis and protection. The thesis presents evidence for a molecular interaction between transmembrane mucins and PDZ adaptor proteins, a relationship that further connects transmembrane mucins to ion channels in the intestine. The results also cast light on the stability of the SEA domain in exposed mucins on cell membranes and suggest that the SEA domain acts as a protective device against mechanical stress exerted on cell membranes.

## **Transmembrane mucins display specificity towards PDZ proteins**

Our data show that the binding of certain transmembrane mucins to their corresponding PDZ binding partners is specific. Despite the presence of a class I PDZ motif in both MUC3 and MUC12, the binding specificity of PDZK1 is strictly limited to the class I PDZ motif of MUC17. Similarly, MUC3 binds GOPC while MUC12 and MUC17 display either no or very weak binding towards GOPC. This phenomenon can be explained by the fact that the selection specificity of PDZ domains depends on amino acid as far as at position -8 and is not solely restricted to the residues at positions 0 and -2 [66, 209]. The interaction between MUC3 and GOPC was in fact completely inhibited when MUC3CT was truncated at position -5. Published data indicate that consensus

sequences categorized as Class I PDZ motifs are not as rigid as previously reported but in reality much more flexible and discrete. All four amino acids, ranging from position 0 to -4, are involved in selectivity for the binding pocket of a PDZ domain [210]. These properties have been suggested to diminish cross-reactivity between PDZ domains and ligands with identical PDZ motif classifications. Besides specificity based on amino acid sequence, co-regulated gene expression and colocalization of PDZ domains and their corresponding ligands, render more complex PDZ-mediated networks. This explains the fact that human MUC17 is able to interact with murine Pdzk1 in the same extent as Muc3(17), thus proving a conserved functional relationship between MUC17 and PDZK1 across human and mouse species. Our findings are supported by the documented correlation between expansion of PDZ domains and increased organism complexity [209].

### **PDZ proteins regulate mucin expression and subcellular localization**

Reports from Gentsch *et al.* indicate that GOPC suppresses overall levels of CFTR and immunocytochemistry proved that GOPC also suppressed CFTR levels in the plasma membrane [206]. The fact that GOPC reduces CFTR Cl<sup>-</sup> currents strengthens these conclusions [199]. Therefore, we were surprised when GOPC suppressed overall levels of MUC3 but did not affect plasma membrane levels of the mucin. There are possible explanations for this finding. First, the existence of MUC3-containing recycling endosomes could guarantee stable levels of MUC3 in the cell membrane even when total protein amounts decrease. Secondly, higher amounts of GOPC than used in our experiments could be required in order to suppress membrane levels of MUC3. Again, this explanation argues for a mechanism that upholds the half-life of

MUC3 in the cell membrane despite suppressed overall levels of the protein. Certainly, additional experiments are required to address this issue.

We also showed that Pdzk1 is necessary for membrane-tethering of Muc3(17) in enterocytes. Muc3(17) in Pdzk1<sup>-/-</sup> mice was localized in intracellular vesicles below the apical membrane. The question that arises is whether Pdzk1 is involved in trafficking of Muc3(17) to the plasma membrane or if Pdzk1 is involved in endocytosis of Muc3(17). Published data on the interaction of PDZK1 with NHE3, indicate that PDZK1 is important for retention of the exchanger in the BBM under basal conditions [73]. It has also been shown that the Class I PDZ motif of CFTR is an apical retention motif and that it is vital for CFTR recycling to the membrane but that it does not affect apical membrane endocytosis of CFTR [198]. Hence, data regarding NHE3 and CFTR trafficking and membrane-retention point towards the need for PDZK1 in recycling of MUC17 to the apical membrane. It is likely that MUC17 resides in recycling endosomes in absence of PDZK1, although this remains to be proven.

### **Membrane mucins and ion channels are co- and counter-regulated**

This thesis reveals an intimate relationship between transmembrane mucins and the ion channels CFTR and NHE3. MUC3 expression can be regulated by CFTR and vice versa, via GOPC in the *trans*-Golgi network. Carbachol-induced endocytosis of MUC17 occurs simultaneously with internalization of NHE3 and recruitment of CFTR to the apical membrane. What do these results mean and what is the underlying purpose of the relationship between transmembrane mucins and ion channels in the small intestine?

Early studies of the intestinal phenotype of CF mice showed that CF pathology is mild in the duodenum and

increases distally, most likely due to a thickened mucus layer and increased bacterial load [211]. Recent data on mucus formation reveal that a functional CFTR ion channel and bicarbonate secretion are vital for mucus hydration and expansion [41]. In CF, a disease that is characterized by a non-functional CFTR and impaired secretion of  $\text{HCO}_3^-$ , the expelled mucus remains anchored to the epithelium. This phenotype can be rescued by addition of high concentration of  $\text{HCO}_3^-$  to the apical solution into which the mucus is released. In healthy tissue, NHE3 counteracts CFTR-mediated mucin hydration and expansion through absorption of  $\text{Na}^+$  coupled to secretion of  $\text{H}^+$  that neutralizes  $\text{HCO}_3^-$ . Therefore, in a scenario which requires CFTR recruitment and activation, NHE3 has to be removed from cell membranes and deactivated.

Protection from commensal and pathogenic bacteria is an important role of secreted mucins. Recent evidence shows that carbachol stimulates mucus discharge from goblet cells of the small intestine and colon, thus resulting in extensive flushing of the intestinal lumen and removal of bacteria entrapped in the mucus overlying the epithelium [8, 212]. Up to now, the fate of the transmembrane mucins during secretion has not been determined. Our results point towards a mechanism where increased secretion and decreased absorption in response to carbachol occurs as transmembrane mucin MUC17 is removed from the cell surface.

Plasma membrane-anchored MUC17 presents an array of *O*-glycans to the outer environment of the cell. These *O*-glycans are suitable attachment sites for bacteria that have penetrated the luminal floating mucus network. In a scenario where bacteria induce secretion, i.e. membrane recruitment and activation of CFTR hand in hand with NHE3 deactivation and endocytosis, the internalization of MUC17 could either act as a way for the cell to eliminate luminal bacteria in the vicinity of the epithelial surface or act as a mechanism that couples



cellular and immunological responses to the specific bacteria. Indeed, MUC1 which is expressed in lung epithelia possesses a signal transduction machinery that is activated upon interaction with *P. aeruginosa* [213]. So far, no signaling pathway associated with MUC17 has been identified but a possible signaling pathway could involve the attachment of bacteria to the mucin domain of MUC17, followed by conformational changes in the SEA domain that in turn induce intracellular signaling. However, this remains to be elucidated.

To summarize, further studies are required for a deeper understanding of the role of transmembrane mucin in cellular responses to bacterial insult in the small intestine.

### **The SEA domain acts as a protective device**

SEA-type mucins, such as MUC1, MUC3, MUC12, and MUC17, are cleaved during biosynthesis in the endoplasmic reticulum. An autocatalytic strain-dependent cleavage renders a mucin heterodimer that remains associated via the SEA domain and once the mucin is presented on the cell surface. In this thesis, we determined the forces required for the dissociation of this heterodimer into its two distinct components; an extracellular subunit composed of a mucin domain and a C-terminal subunit that is anchored to the cell membrane through a type I transmembrane domain. The C-terminal subunit also contains a cytoplasmic tail that harbors binding motifs for various intracellular adaptor proteins and sequences which can be phosphorylated by kinases.

Our experiments showed that a force with the magnitude of approximately 170 pN at a loading rate of  $25\text{ nNs}^{-1}$  was able to break a single SEA domain. The dissociation force of the SEA domain should be understood in relation to forces exerted on membrane proteins in general and membrane proteins in epithelial cells in particular. A membrane protein is anchored to the plasma membrane via hydrophobic interactions between

the membrane-spanning amino acids of the protein and the surrounding lipids. Furthermore, a membrane protein is anchored to the intracellular cytoskeleton via scaffolding proteins. These two components contribute to a force of 400-600 pN that has to be overcome in order to extract a single membrane protein from the plasma membrane [214]. Thus, when mechanical forces are exerted on a SEA membrane protein, SEA dissociation occurs long before the plasma membrane is affected. This is an indication of the protective role of SEA mucins expressed on cell surfaces.

MUC1 is expressed in the lungs where vigorous and constant ciliary beating generates a force of approximately 60 pN [215]. Based on our data, the SEA domain of MUC1 is resistant to the forces rendered by beating cilia. A second case to take into consideration is binding of bacteria to SEA-type mucins on enterocytes of the intestine. Due to the constant flow of fluid towards distal segments, the mass of a single *E. Coli* bacteria would assert a force of approximately  $10^{-14}$  N on a single SEA mucin [216]. Consequently, over 15,000 bacteria are required to break a single SEA domain. Thus, we conclude that transmembrane mucins with a cleavable SEA domain are resistant to mechanical forces from bacteria. However, as previously mentioned, there is a possibility that bacterial binding generates conformational changes in the mucin that in turn results in intracellular signaling and a subsequent cellular response. Moreover, bacteria bound to transmembrane mucins could enzymatically break down these glycoproteins.

In summary, the SEA domain of transmembrane mucins is resistant to forces below 170 pN and can withstand both bacterial binding in the intestine and ciliary beating in the lungs. Thus, SEA mucins act as protective devices on cell surfaces.

## Future perspectives

---

The results presented in this thesis have shed light on features and properties of transmembrane mucins that were previously not known. Still, several important questions remain to be addressed. One important issue is the dynamics of transmembrane mucins in the plasma membrane of polarized cells. The membrane trafficking of MUC1 has been extensively studied [188, 189]. However, the major transmembrane mucins of the small intestine, MUC3, MUC12, and MUC17, lack many binding motifs found in the cytoplasmic tail of MUC1, while MUC1 lacks the PDZ motif in the C-termini of MUC3, MUC12, and MUC17. Therefore, it is likely that trafficking of MUC3, MUC12, and MUC17 in cell membranes displays alternate dynamics as it is regulated by other intracellular adaptor proteins than those involved in MUC1 trafficking. This thesis has already presented evidence for clathrin-dependent endocytosis of MUC17, mediated through an AP-2 binding site on MUC17CT. Therefore, a systematic characterization of the cytoplasmic tails of MUC3, MUC12, and MUC17 could reveal novel interaction sites that are involved in trafficking of these mucins.

A second issue to address is the potential binding of commensal and pathogenic bacteria to the intestinal transmembrane mucins. As mentioned, transmembrane mucins harbor heavily *O*-glycosylated mucin domains that may act as binding sites for bacteria. Besides identifying species of bacteria with the ability to interact with these mucin domains, it is intriguing to consider bacterial binding to transmembrane mucins as a cellular monitoring system involving internalization of bound bacteria. Indeed, this thesis has presented proof for carbachol-induced MUC17 endocytosis. It remains to be shown if bacteria accompany MUC17 into the cell and if so, whether endocytosed bacteria are degraded

by the cell and/or presented to the immune system. The latter process has recently been shown to take place in goblet cells [217]. Based on the existing knowledge on cellular responses to commensal and pathogenic bacteria, an assessment of a sensory mechanism mediated by transmembrane mucins is important.

Galectin-3, an endogenous beta-galactoside-binding lectin, has been shown to interact and colocalize with MUC1 in human conjunctival epithelium [218]. It has been argued that the formation of an epithelial barrier is facilitated by binding of galectin-3 to MUC1. These findings should be exploited in the context of intestinal barrier function. The fact that enterocytes express galectins makes it likely that these endogenous lectins are involved in the organization of the glycocalyx by multivalent interactions with cell surface mucins. Again, assessment of the mechanisms behind transmembrane mucin organization at the cell surface is important for a deeper understanding of the role of epithelial cell in protection against and immune responses towards pathogens.

The highly conserved SEA domains of MUC1, MUC3, MUC12, and MUC17 have evolved to permit their own dissociation. The data presented in this thesis show that the SEA domain dissociates when mechanical forces are applied to it. The question that arises is if conformational changes in SEA domains, generated by mechanical forces from the extracellular environment, can be interpreted into intracellular signals and if these signals result in appropriate cell responses to mechanical stress. Also, an interesting feature of the MUC1 SEA domain is two hydrophobic patches on the otherwise polar surface of the folded domain [28]. These patches have been suggested as binding sites for other proteins. Thus, binding studies involving human and bacterial surface proteins could disclose novel extracellular interaction partners for SEA membrane mucins.

## Populärvetenskaplig sammanfattning

---

Människokroppen täcks av ett hudlager som fungerar som en skyddsbarriär gentemot främmande och skadliga ämnen i vår omgivning. På liknande sätt, skyddas de inre organen som är i direkt kontakt med denna omgivning av ett tjockt slemlager som också kallas mukus. Detta slem, som hittas såväl i mag- och tarmkanalen som i våra lungor, är ett välordnat nätverk av proteiner som fångar upp goda och skadliga mikroorganismer för att transportera dessa vidare ut ur kroppen. Huvudkomponenten i slemmet är stora proteiner som kallas muciner. En undergrupp av muciner utsöndras från specialiserade slemproducerande celler och bildar ett skyddande slemlager över den underliggande cellytan. Den andra undergruppen består av membranbundna muciner som bildas i epitelceller och som förblir fast förankrade på ytan av dessa celler.

Målet med denna avhandling har varit att identifiera tidigare okända interaktioner mellan membranbundna muciner och s.k. PDZ-proteiner som organiserar de olika proteinerna på cellens yta. Vidare, har studier gjorts för att se om dessa identifierade PDZ-proteiner fungerar som gemensamma kopplingsstationer för membranbundna muciner och jonkanalerna som har visat sig viktiga för bildandet av ett välfungerande slemlager. En tredje frågeställning som har besvarats är om membranbundna muciner kan stå emot mekaniska krafter utifrån och därmed skydda de celler som de är förankrade i.

Resultaten som presenteras i denna avhandling visar att membranbundna muciner samspelar med två PDZ-proteiner som i sin tur kan interagera med viktiga jonkanaler i tunntarmen. Det membranbundna mucinet MUC17 binds upp av ett PDZ-protein som är nödvändigt för att mucinet ska förankras till cellytan. Resultatet visar dessutom att mängden av det membranbundna mucinet MUC3 regleras av jonkanalen CFTR och vice versa. Detta sker via ett annat PDZ-protein. Avhandlingen demonstrerar också att stimulans som leder till ökad tarmsekretion och minskad absorption resulterar i att MUC17 transporteras tillbaka in i cellen. Slutligen, presenterar vi bevis på att den svagaste länken i många transmembranösa muciner har förmågan att absorbera mekaniska krafter för att på så sätt skydda cellmembranet mot mekanisk stress från omgivningen.

Sammanfattningsvis åskådliggör denna avhandling ett intimt samspel mellan membranbundna muciner och jonkanaler i tunntarmen. Dessa tidigare okända interaktioner skapar en bättre förståelse för hur tunntarmens celler reagerar på goda och skadliga mikroorganismer som är i nära kontakt med dessa celler.

## **Additional bibliography**

---

Johansson, M. E., Ambort, D., **Pelaseyed, T.**, Schutte, A., Gustafsson, J. K., Ermund, A., Subramani, D. B., Holmen-Larsson, J. M., Thomsson, K. A., Bergstrom, J. H., van der Post, S., Rodriguez-Pineiro, A. M., Sjovall, H., Backstrom, M. and Hansson, G. C. (2011) Composition and functional role of the mucus layers in the intestine. *Cell Mol Life Sci.* **68**, 3635-3641

## Acknowledgements

---

This thesis is the outcome of a journey that started in the fall of 2005, when I started working on my master thesis project. During the seven years that have passed since my first stumbling steps into the world of mucins, I have had the privilege to work with people that have dedicated their lives to science. This thesis would have never seen the light of day without the inspiration of these individuals.

**Gunnar**, you have been an endless source of knowledge and guidance. You gave me the chance to explore an intriguing scientific field in which you have made tremendous advances. And I am grateful that you gave me the opportunity to be a part of that. The door to your office has literally always been open. I have felt great comfort in approaching you with questions regarding my science projects and also your interest in my well-being, both in the lab and in my ordinary life. This has been invaluable. Thank you!

My first contact with mucins was conducted under the close supervision of **Martin**. I will never forget your patience and diligence during my master thesis project. The PCR problems we encountered (due to another lab providing us with wrong template plasmid!) taught me four words: Do not give up! Thanks to **Emily** for involving me in the PDZ project. **Malin J**, thank you for your advice regarding all experimental setups I encountered during these years. You are a scientist with a genuine curiosity for those mysteries that Mother Nature conceals. **Malin B**, thank you for all the advice regarding immunotechniques and the FACS machine. **Dan**, your advice has saved me on numerous times. Your broad experience has been vital for the projects presented in this thesis. **Karin**, what would the lab be without you? Thanks for the talks, jokes and all the laughs. **Catharina**, thanks for keeping an eye on all the reagents I ordered. **Joakim**, thanks for teaming up with me in setting up the Mucin Beer Club that has provided so many thirsty scientists with beverages followed by terrible headaches on Saturday mornings. Your relaxed attitude towards you challenging projects is admirable. Good luck! **Frida**, thanks for all the laughs, talks and the company during the long AFM measurements. Your input into that project was crucial. Good luck with your new position! **Jenny**, you have been absolutely irreplaceable regarding my understanding of ion channels. You have helped me answer many complex questions. Good luck with your future research. **Sjoerd**, your ideas are always fascinating and you have the eye for finesse, both in science and in life. **Ana**, thanks for various advice regarding MS-related data and statistical analysis. You know your science! **Daniel** a.k.a. “Lord of the Rings”, stay out of trouble and don’t go anywhere near Sticky Fingers again. It will damage your health. Compañero **Robert**, I know that the Swedish climate hasn’t been kind to you but I hope that I have contributed to making your stay a bit more comfortable. You have certainly been an injection of energy. **André**, good luck with your project. I am looking forward to the next Christmas party where I expect you will put on a show melting sugar into the rum. **Christian**, take care of Heinz *et al.* and good luck with your project. **Elisabeth**, it was always nice discussing family matters with you. Good luck with little baby that is on the way. **Rickard**, thanks for the nice discussions in the lunch room. **Hedvig**, I know that you are conducting some complicated science that I just can’t begin to understand. Good luck! **Ida**, thank you for all the help with the MUC17 project. You are always precise and you are always questioning the outcome of experiments. Those are qualities to hold on to! **Markus**, your enthusiasm for your student project is astonishing. I hope I can guide you through it as good as I possibly can. **Anna**, I have enjoyed your creative efforts to describe the properties of the mucus from different mouse models. Keep it up! **Jessica** and **Tina**, I’ll miss

all the talks and all the laughter. Take care, wherever you are. **Julia**, I will always remember the dance lessons! **Koviljka**, I'll miss all the talks about vacations in the Balkans. **Karolina**, good luck with the science and all the clinical work. **Lisbeth**, thanks for the talks in the lunch room. **Elisabeth N.** and **Catharina**, good luck in the future. You have what it takes.

Thanks also to the members of **Niclas's**, **Sussan's** and **Sara's** research groups. I have enjoyed your company during lunch hours and on various other occasions.

I would have never managed to make it through all this without my beautiful family. **Amela**, you have been by my side all the way. None of this would have been possible without your love and endless support. It doesn't go a day without me thinking of how I can make it up to you. You will always be my love and my best friend. Volim te! My dear little **Soraya**, you made my life whole when you arrived that November afternoon. Nothing beats the feeling of coming home and being drowned by you hugs and kisses. I hope that someday, when you have grown up, you will feel that I have been a good father and that you will regard me not only as a father but also as a good friend you can talk to about anything. **Massoud** and **Shahin**, my dear parents, you have climbed mountains, crossed deserts and overcome great dangers to bring our family to safety. I will always be in debt to you and I will honor your efforts by living my life as good and just as I possibly can. My dear brother, **Homan**, nothing can stop you when you have put your heart into something. I am trying to learn from you but it is hard work. I love you. **Hanna**, I am so happy that you are a part of our family. My dear **Alice**, I will miss you so much while you are in Germany. Don't forget your Godfather! **Pete**, you are simply the coolest gentlemen. Thanks for reading through my thesis and thank you for taking care of Soraya when her parents have been occupied with work. **Saliha** and **Mahmut**, you have both been an enormous support and I will never be able to pay back your love and hospitality. **Elma**, you are truly full of energy. For a long time I have wished to join you on a night out and now that this thesis is complete, I hope that we can party all night long, at least once.

**Nazem**, my friend, you have always been there and you have always been an inspiration. You're a companion that I will always hold very dear. **Gilak** and **Reza**, thank you for all the late nightly conversations and your great friendship.

This last one goes out to all of you that have devoted your lives to changing the world. Keep up the good work!

---

This work has been supported by the Swedish Research Council (no. 7461, 21027, and 342-2004-4434), The Swedish Cancer Foundation, The Knut and Alice Wallenberg Foundation, IngaBritt and Arne Lundberg Foundation, Sahlgren's University Hospital (LUA-ALF), Wilhelm and Martina Lundgren's Foundation, Torsten och Ragnar Söderbergs Stiftelser, The Sahlgrenska Academy, National Institute of Allergy and Infectious Diseases (U01AI095473, the content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH), The Swedish Foundation for Strategic Research - The Mucus-Bacteria-Colitis Center (MBC) of the Innate Immunity Program, The Swedish CF Foundation, Erica Lederhausen's Foundation, and Lederhausen's Center for CF Research at Univ. Gothenburg. I acknowledge the Centre for Cellular Imaging at the University of Gothenburg for technical help.



## References

---

1. Johansson, M.E., et al., *Composition and functional role of the mucus layers in the intestine*. Cell Mol Life Sci, 2011. **68**(22): p. 3635-41.
2. Lang, T., G.C. Hansson, and T. Samuelsson, *Gel-forming mucins appeared early in metazoan evolution*. Proc Natl Acad Sci U S A, 2007. **104**(41): p. 16209-14.
3. Gendler, S., et al., *A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats*. J Biol Chem, 1988. **263**(26): p. 12820-3.
4. Hollingsworth, M.A. and B.J. Swanson, *Mucins in cancer: protection and control of the cell surface*. Nat Rev Cancer, 2004. **4**(1): p. 45-60.
5. Lang, T., et al., *Bioinformatic identification of polymerizing and transmembrane mucins in the puffer fish *Fugu rubripes**. Glycobiology, 2004. **14**(6): p. 521-7.
6. Moniaux, N., et al., *Characterization of Human Mucin MUC17*. J Biol Chem, 2006. **281**(33): p. 23676-23685.
7. Loomes, K.M., et al., *Functional protective role for mucin glycosylated repetitive domains*. Eur J Biochem, 1999. **266**(1): p. 105-111.
8. Johansson, M.E.V., et al., *The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria*. Proc Natl Acad Sci U S A, 2008. **105**(39): p. 15064-15069.
9. Gendler, S.J. and A.P. Spicer, *Epithelial Mucin Genes*. Annu Rev Physiol, 1995. **57**(1): p. 607-634.
10. Bobek, L.A., et al., *Molecular cloning, sequence, and specificity of expression of the gene encoding the low molecular weight human salivary mucin (MUC7)*. J Biol Chem, 1993. **268**(27): p. 20563-9.
11. Escande, F., et al., *The mouse secreted gel-forming mucin gene cluster*. BBA- Gene Struct Expr, 2004. **1676**(3): p. 240-250.
12. Perez-Vilar, J. and R.L. Hill, *The structure and assembly of secreted mucins*. J Biol Chem, 1999. **274**(45): p. 31751-4.

13. Cha, B., et al., *The NHE3 Juxtamembrane Cytoplasmic Domain Directly Binds Ezrin: Dual Role in NHE3 Trafficking and Mobility in the Brush Border*. *Mol Biol Cell*, 2006. **17**(6): p. 2661-2673.
14. Godl, K., et al., *The N terminus of the MUC2 mucin forms trimers that are held together within a trypsin-resistant core fragment*. *J Biol Chem*, 2002. **277**(49): p. 47248-56.
15. Yun, C.-H.C., et al., *NHE3 Kinase A Regulatory Protein E3KARP Binds the Epithelial Brush Border Na<sup>+</sup>/H<sup>+</sup> Exchanger NHE3 and the Cytoskeletal Protein Ezrin*. *J Biol Chem*, 1998. **273**(40): p. 25856-25863.
16. Lamprecht, G., E.J. Weinman, and C.-H.C. Yun, *The Role of NHERF and E3KARP in the cAMP-mediated Inhibition of NHE3*. *J Biol Chem*, 1998. **273**(45): p. 29972-29978.
17. Ward, C.L. and R.R. Kopito, *Intracellular turnover of cystic fibrosis transmembrane conductance regulator: Inefficient processing and rapid degradation of wild-type and mutant proteins*. *J Biol Chem*, 1994. **269**(41): p. 25710-8.
18. Gum, J.R., et al., *Molecular cloning of cDNAs derived from a novel human intestinal mucin gene*. *Biochem Biophys Res Commun*, 1990. **171**(1): p. 407-415.
19. Lukacs, G.L., et al., *Constitutive internalization of cystic fibrosis transmembrane conductance regulator occurs via clathrin-dependent endocytosis and is regulated by protein phosphorylation*. *Biochem J*, 1997. **328**: p. 353-61.
20. Williams, S.J., et al., *Two novel mucin genes down-regulated in colorectal cancer identified by differential display*. *Cancer Res*, 1999. **59**(16): p. 4083-9.
21. Kim, J.H., et al., *Ca<sup>2+</sup>-dependent Inhibition of Na<sup>+</sup>/H<sup>+</sup> Exchanger 3 (NHE3) Requires an NHE3-E3KARP- $\alpha$ -Actinin-4 Complex for Oligomerization and Endocytosis*. *J Biol Chem*, 2002. **277**(26): p. 23714-23724.
22. McLachlan, G., et al., *Laboratory and clinical studies in support of cystic fibrosis gene therapy using pCMV-CFTR-DOTAP*. *Gene therapy*, 1996. **3**(12): p. 1113-23.
23. Dorin, J.R., et al., *A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction*. *Gene Ther*, 1996. **3**(9): p. 797-801.

24. Gum, J.R., et al., *MUC17, a Novel Membrane-Tethered Mucin*. *Biochem Biophys Res Commun*, 2002. **291**(3): p. 466-475.
25. Ramalho, A.S., et al., *Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis*. *Am J Respir Cell Mol Biol*, 2002. **27**(5): p. 619-27.
26. Lang, T., G.C. Hansson, and T. Samuelsson, *An inventory of mucin genes in the chicken genome shows that the mucin domain of Muc13 is encoded by multiple exons and that ovomucin is part of a locus of related gel-forming mucins*. *BMC Genomics*, 2006. **7**: p. 197.
27. Ligtenberg, M.J., et al., *Cell-associated episialin is a complex containing two proteins derived from a common precursor*. *J Biol Chem*, 1992. **267**(9): p. 6171-7.
28. Macao, B., et al., *Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin*. *Nat Struct Mol Biol*, 2006. **13**(1): p. 71-6.
29. Parry, S., et al., *Identification of MUC1 proteolytic cleavage sites in vivo*. *Biochem Biophys Res Commun*, 2001. **283**(3): p. 715-20.
30. Yin, B.W.T. and K.O. Lloyd, *Molecular Cloning of the CA125 Ovarian Cancer Antigen*. *J Biol Chem*, 2001. **276**(29): p. 27371-27375.
31. Maeda, T., et al., *Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16)*. *J Biol Chem*, 2004. **279**(13): p. 13174-82.
32. Moniaux, N., et al., *Structural organization and classification of the human mucin genes*. *Front Biosci*, 2001. **6**: p. D1192-206.
33. Soto, P., J. Zhang, and K.L. Carraway, *Enzymatic cleavage as a processing step in the maturation of Muc4/sialomucin complex*. *J Cell Biochem*, 2006. **97**(6): p. 1267-1274.
34. Lidell, M.E., M.E. Johansson, and G.C. Hansson, *An autocatalytic cleavage in the C terminus of the human MUC2 mucin occurs at the low pH of the late secretory pathway*. *J Biol Chem*, 2003. **278**(16): p. 13944-51.

35. Lidell, M.E. and G.C. Hansson, *Cleavage in the GDPH sequence of the C-terminal cysteine-rich part of the human MUC5AC mucin*. *Biochem J*, 2006. **399**(1): p. 121-9.
36. Gendler, S.J., et al., *Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin*. *J Biol Chem*, 1990. **265**(25): p. 15286-93.
37. Gendler, S.J., *MUC1, the renaissance molecule*. *J Mammary Gland Biol Neoplasia*, 2001. **6**(3): p. 339-53.
38. Baruch, A., et al., *The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein*. *Cancer Res*, 1999. **59**(7): p. 1552-61.
39. Hinojosa-Kurtzberg, A.M., et al., *Novel MUC1 splice variants contribute to mucin overexpression in CFTR-deficient mice*. *Am J Physiol Gastrointest Liver Physiol*, 2003. **284**(5): p. G853-62.
40. Hartman, M., et al., *MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer*. *Int J Cancer*, 1999. **82**(2): p. 256-67.
41. Gustafsson, J.K., et al., *Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype*. *J Exp Med*, 2012. **209**(7): p. 1263-1272.
42. Schroeder, J.A., et al., *Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland*. *J Biol Chem*, 2001. **276**(16): p. 13057-64.
43. Gianni, S., et al., *The kinetics of PDZ domain-ligand interactions and implications for the binding mechanism*. *J Biol Chem*, 2005. **280**(41): p. 34805-12.
44. Ito, S., *Structure and function of the glycocalyx*. *Fed Proc*, 1969. **28**(1): p. 12-25.
45. Li, Y., et al., *The c-Src Tyrosine Kinase Regulates Signaling of the Human DF3/MUC1 Carcinoma-associated Antigen with GSK3 $\beta$  and  $\beta$ -Catenin*. *J Biol Chem*, 2001. **276**(9): p. 6061-6064.
46. Wen, Y., et al., *Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin*. *J Biol Chem*, 2003. **278**(39): p. 38029-39.

47. Wei, X., H. Xu, and D. Kufe, *Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response*. *Cancer Cell*, 2005. **7**(2): p. 167-78.
48. Singh, P.K., et al., *Phosphorylation of MUC1 by Met Modulates Interaction with p53 and MMP1 Expression*. *J Biol Chem*, 2008. **283**(40): p. 26985-26995.
49. Lan, M.S., et al., *Cloning and sequencing of a human pancreatic tumor mucin cDNA*. *J Biol Chem*, 1990. **265**(25): p. 15294-9.
50. Pratt, W.S., et al., *Multiple Transcripts of MUC3: Evidence for Two Genes, MUC3A and MUC3B*. *Biochem Biophys Res Commun*, 2000. **275**(3): p. 916-923.
51. Baeckström, D., N. Karlsson, and G.C. Hansson, *Purification and characterization of sialyl-Le(a)-carrying mucins of human bile; evidence for the presence of MUC1 and MUC3 apoproteins*. *J Biol Chem*, 1994. **269**(20): p. 14430-14437.
52. Malmberg, E.K., et al., *Increased levels of mucins in the cystic fibrosis mouse small intestine, and modulator effects of the Muc1 mucin expression*. *Am J Physiol Gastrointest Liver Physiol*, 2006. **291**(2): p. G203-10.
53. Khatri, I.A., et al., *Characteristics of rodent intestinal mucin Muc3 and alterations in a mouse model of human cystic fibrosis*. *Am J Physiol Gastrointest Liver Physiol*, 2001. **280**(6): p. G1321-30.
54. Luu, Y., et al., *Human intestinal MUC17 mucin augments intestinal cell restitution and enhances healing of experimental colitis*. *Int J Biochem Cell Biol*, 2010. **42**(6): p. 996-1006.
55. Resta-Lenert, S., et al., *Muc17 protects intestinal epithelial cells from enteroinvasive E. coli infection by promoting epithelial barrier integrity*. *Am J Physiol Gastrointest Liver Physiol*, 2011. **300**(6): p. G1144-G1155.
56. Schultz, J., et al., *SMART: a web-based tool for the study of genetically mobile domains*. *Nucleic Acids Res*, 2000. **28**(1): p. 231-4.
57. Jelen, F., et al., *PDZ domains - common players in the cell signaling*. *Acta Biochim Pol*, 2003. **50**(4): p. 985-1017.

58. Rambourg, A., M. Neutra, and C.P. Leblond, *Presence of a "cell coat" rich in carbohydrate at the surface of cells in the rat*. *Anat Rec*, 1966. **154**(1): p. 41-71.
59. Wilson, C. and A. Ragnini-Wilson, *Conserved molecular mechanisms underlying homeostasis of the Golgi complex*. *Int J Cell Biol*, 2010. **2010**: p. 758230.
60. Kim, E., et al., *Clustering of Shaker-type K<sup>+</sup> channels by interaction with a family of membrane-associated guanylate kinases*. *Nature*, 1995. **378**(6552): p. 85-8.
61. Kornau, H.C., et al., *Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95*. *Science*, 1995. **269**(5231): p. 1737-40.
62. Niethammer, M., E. Kim, and M. Sheng, *Interaction between the C terminus of NMDA receptor subunits and multiple members of the PSD-95 family of membrane-associated guanylate kinases*. *J Neurosci*, 1996. **16**(7): p. 2157-63.
63. Doyle, D.A., et al., *Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ*. *Cell*, 1996. **85**(7): p. 1067-76.
64. Arvan, P. and D. Castle, *Sorting and storage during secretory granule biogenesis: Looking backward and looking forward*. *Biochem J*, 1998. **332**(3): p. 593-610.
65. Emi, Y., et al., *ATP-binding cassette transporter isoform C2 localizes to the apical plasma membrane via interactions with scaffolding protein*. *J Biochem*, 2011. **149**(2): p. 177-189.
66. Songyang, Z., et al., *Recognition of unique carboxyl-terminal motifs by distinct PDZ domains*. *Science*, 1997. **275**(5296): p. 73-7.
67. Stricker, N.L., et al., *PDZ domain of neuronal nitric oxide synthase recognizes novel C-terminal peptide sequences*. *Nat Biotechnol*, 1997. **15**(4): p. 336-42.
68. Karthikeyan, S., T. Leung, and J.A. Ladias, *Structural basis of the Na<sup>+</sup>/H<sup>+</sup> exchanger regulatory factor PDZ1 interaction with the carboxyl-terminal region of the cystic fibrosis transmembrane conductance regulator*. *J Biol Chem*, 2001. **276**(23): p. 19683-6.

69. Tochio, H., et al., *Solution structure of the extended neuronal nitric oxide synthase PDZ domain complexed with an associated peptide*. *Nat Struct Biol*, 1999. **6**(5): p. 417-21.
70. Kozlov, G., K. Gehring, and I. Ekiel, *Solution structure of the PDZ2 domain from human phosphatase hPTP1E and its interactions with C-terminal peptides from the Fas receptor*. *Biochemistry*, 2000. **39**(10): p. 2572-80.
71. Niethammer, M., et al., *CRIP1, a novel postsynaptic protein that binds to the third PDZ domain of PSD-95/SAP90*. *Neuron*, 1998. **20**(4): p. 693-707.
72. Malmberg, E.K., et al., *Bcr (breakpoint cluster region) protein binds to PDZ-domains of scaffold protein PDZK1 and vesicle coat protein Mint3*. *J Cell Sci*, 2004. **117**(Pt 23): p. 5535-41.
73. Zachos, N.C., et al., *NHERF3 (PDZK1) Contributes to Basal and Calcium Inhibition of NHE3 Activity in Caco-2BBE Cells*. *J Biol Chem*, 2009. **284**(35): p. 23708-23718.
74. Short, D.B., et al., *An Apical PDZ Protein Anchors the Cystic Fibrosis Transmembrane Conductance Regulator to the Cytoskeleton*. *J Biol Chem*, 1998. **273**(31): p. 19797-19801.
75. Moyer, B.D., et al., *The PDZ-interacting domain of cystic fibrosis transmembrane conductance regulator is required for functional expression in the apical plasma membrane*. *J Biol Chem*, 2000. **275**(35): p. 27069-74.
76. Lamprecht, G., et al., *Intestinal Anion Exchanger Down-regulated in Adenoma (DRA) Is Inhibited by Intracellular Calcium*. *J Biol Chem*, 2009. **284**(29): p. 19744-19753.
77. Zhu, W., et al., *The Scavenger Receptor Class B Type I Adaptor Protein PDZK1 Maintains Endothelial Monolayer Integrity*. *Circ Res*, 2008. **102**(4): p. 480-487.
78. Miyazaki, H., et al., *Modulation of Renal Apical Organic Anion Transporter 4 Function by Two PDZ Domain-Containing Proteins*. *J Am Soc Nephrol*, 2005. **16**(12): p. 3498-3506.
79. Wheeler, D., et al., *NHERF-1 and the Cytoskeleton Regulate the Traffic and Membrane Dynamics of G Protein-coupled Receptors*. *J Biol Chem*, 2007. **282**(34): p. 25076-25087.

80. Broere, N., et al., *Defective jejunal and colonic salt absorption and altered-Na<sup>+</sup>/H<sup>+</sup> exchanger 3 (NHE3) activity in NHE regulatory factor 1 (NHERF1) adaptor protein-deficient mice.* Pflug Arch Eur J Physiol, 2009. **457**(5): p. 1079-1091.
81. Haggie, P.M., et al., *Tracking of Quantum Dot-labeled CFTR Shows Near Immobilization by C-Terminal PDZ Interactions.* Mol Biol Cell, 2006. **17**(12): p. 4937-4945.
82. Kwon, S.H., H. Pollard, and W.B. Guggino, *Knockdown of NHERF1 Enhances Degradation of Temperature Rescued ΔF508 CFTR from the Cell Surface of Human Airway Cells.* Cell Physiol Biochem, 2007. **20**(6): p. 763-772.
83. Favia, M., et al., *Na<sup>+</sup>/H<sup>+</sup> Exchanger Regulatory Factor 1 Overexpression-dependent Increase of Cytoskeleton Organization Is Fundamental in the Rescue of F508del Cystic Fibrosis Transmembrane Conductance Regulator in Human Airway CFBE41o- Cells.* Mol Biol Cell, 2010. **21**(1): p. 73-86.
84. Davis, A.S., et al., *Mechanism of Inducible Nitric Oxide Synthase Exclusion from Mycobacterial Phagosomes.* PLoS Pathog, 2007. **3**(12): p. e186.
85. LaLonde, D.P. and A. Bretscher, *The Scaffold Protein PDZK1 Undergoes a Head-to-Tail Intramolecular Association That Negatively Regulates Its Interaction with EBP50.* Biochemistry, 2009. **48**(10): p. 2261-2271.
86. LaLonde, D.P., D. Garbett, and A. Bretscher, *A Regulated Complex of the Scaffolding Proteins PDZK1 and EBP50 with Ezrin Contribute to Microvillar Organization.* Mol Biol Cell, 2010. **21**(9): p. 1519-1529.
87. Cheng, J., H. Wang, and W.B. Guggino, *Modulation of mature cystic fibrosis transmembrane regulator protein by the PDZ domain protein CAL.* J Biol Chem, 2004. **279**(3): p. 1892-8.
88. Cheng, H. and C.P. Leblond, *Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine I. Columnar cell.* Am J Anat, 1974. **141**(4): p. 461-479.
89. Cheng, H., *Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine II. Mucous cells.* Am J Anat, 1974. **141**(4): p. 481-501.
90. Venkatasubramanian, J., M. Ao, and M.C. Rao, *Ion transport in the small intestine.* Curr Opin Gastroen, 2010. **26**(2): p. 123-128.



91. Kirk, K.L., D.R. Halm, and D.C. Dawson, *Active sodium transport by turtle colon via an electrogenic Na-K exchange pump*. *Nature*, 1980. **287**(5779): p. 237-239.
92. Kaplan, J.H., *Sodium ions and the sodium pump: transport and enzymatic activity*. *Am J Physiol Gastrointest Liver Physiol*, 1983. **245**(3): p. G327-G333.
93. Barrett, K.E. and S.J. Keely, *Chloride Secretion by the Intestinal Epithelium: Molecular Basis and Regulatory Aspects*. *Annu Rev Physiol*, 2000. **62**(1): p. 535-572.
94. Payne, J.A. and B. Forbush Iii, *Molecular characterization of the epithelial Na-K-Cl cotransporter isoforms*. *Curr Opin Cell Biol*, 1995. **7**(4): p. 493-503.
95. Mandel, K.G., et al., *Ba<sup>2+</sup> inhibition of VIP- and A23187-stimulated Cl<sup>-</sup> secretion by T84 cell monolayers*. *Am J Physiol-Cell Physiol*, 1986. **250**(3): p. C486-C494.
96. Riordan, J.R., et al., *Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA*. *Science*, 1989. **245**(4922): p. 1066-73.
97. Rommens, J.M., et al., *Identification of the cystic fibrosis gene: chromosome walking and jumping*. *Science*, 1989. **245**(4922): p. 1059-65.
98. Higgins, C.F., et al., *Nucleotide binding by membrane components of bacterial periplasmic binding protein-dependent transport systems*. *Embo J*, 1985. **4**(4): p. 1033-9.
99. Dean, M., *The genetics of ATP-binding cassette transporters*. *Methods Enzymol*, 2005. **400**: p. 409-29.
100. Moyer, B.D., et al., *A PDZ-interacting domain in CFTR is an apical membrane polarization signal*. *J Clin Invest*, 1999. **104**(10): p. 1353-61.
101. Griffiths, G. and K. Simons, *The trans Golgi network: sorting at the exit site of the Golgi complex*. *Science*, 1986. **234**(4775): p. 438-43.
102. Hanrahan, J.W., et al., *Function and dysfunction of the CFTR chloride channel*. *Soc Gen Physiol Ser*, 1995. **50**: p. 125-37.

103. Devor, D.C., et al., *Bicarbonate and chloride secretion in Calu-3 human airway epithelial cells*. J Gen Physiol, 1999. **113**(5): p. 743-60.
104. Choi, J.Y., et al., *Aberrant CFTR-dependent HCO<sub>3</sub><sup>-</sup> transport in mutations associated with cystic fibrosis*. Nature, 2001. **410**(6824): p. 94-7.
105. Gabriel, S.E., et al., *CFTR and outward rectifying chloride channels are distinct proteins with a regulatory relationship*. Nature, 1993. **363**(6426): p. 263-8.
106. Reddy, M.M., M.J. Light, and P.M. Quinton, *Activation of the epithelial Na<sup>+</sup> channel (ENaC) requires CFTR Cl<sup>-</sup> channel function*. Nature, 1999. **402**(6759): p. 301-4.
107. Garcia, M.A., N. Yang, and P.M. Quinton, *Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion*. J Clin Invest, 2009. **119**(9): p. 2613-22.
108. Gentzsch, M., et al., *Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator*. Mol Biol Cell, 2004. **15**(6): p. 2684-96.
109. Zielenski, J. and L.C. Tsui, *Cystic fibrosis: genotypic and phenotypic variations*. Annu Rev Genet, 1995. **29**: p. 777-807.
110. Du, K., M. Sharma, and G.L. Lukacs, *The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR*. Nat Struct Mol Biol, 2005. **12**(1): p. 17-25.
111. Jensen, T.J., et al., *Multiple proteolytic systems, including the proteasome, contribute to CFTR processing*. Cell, 1995. **83**(1): p. 129-35.
112. Murer, H., U. Hopfer, and R. Kinne, *Sodium/proton antiport in brush-border-membrane vesicles isolated from rat small intestine and kidney*. Biochem J, 1976. **154**(3): p. 597-604.
113. Sardet, C., A. Franchi, and J. Pouyssegur, *Molecular cloning, primary structure, and expression of the human growth factor-activatable Na<sup>+</sup>/H<sup>+</sup> antiporter*. Cell, 1989. **56**(2): p. 271-80.
114. Grinstein, S., D. Rotin, and M.J. Mason, *Na<sup>+</sup>/H<sup>+</sup> exchange and growth factor-induced cytosolic pH changes. Role in cellular proliferation*. Biochim Biophys Acta, 1989. **988**(1): p. 73-97.

115. Aronson, P.S. and P. Igarashi, *Chapter 4 Molecular Properties and Physiological Roles of the Renal Na<sup>+</sup>-H<sup>+</sup> Exchanger*, in *Current Topics in Membranes and Transport*, F.B.P.S.A. Arnost Kleinzeller and F.B. Walter, Editors. 1986, Academic Press. p. 57-75.
116. Biemesderfer, D., et al., *NHE3: a Na<sup>+</sup>/H<sup>+</sup> exchanger isoform of renal brush border*. *Am J Physiol*, 1993. **265**(5 Pt 2): p. F736-42.
117. Hoogerwerf, W.A., et al., *NHE2 and NHE3 are human and rabbit intestinal brush-border proteins*. *Am J Physiol*, 1996. **270**(1 Pt 1): p. G29-41.
118. Zizak, M., et al., *Na<sup>+</sup>/H<sup>+</sup> Exchanger NHE3 Has 11 Membrane Spanning Domains and a Cleaved Signal Peptide: Topology Analysis Using In Vitro Transcription/Translation*. *Biochemistry*, 2000. **39**(27): p. 8102-8112.
119. Levine, S.A., et al., *Separate C-terminal Domains of the Epithelial Specific Brush Border Na/H Exchanger Isoform NHE3 Are Involved in Stimulation and Inhibition by Protein Kinases/Growth Factors*. *J Biol Chem*, 1995. **270**(23): p. 13716-13725.
120. Wakabayashi, S., et al., *The Na<sup>+</sup>/H<sup>+</sup> antiporter cytoplasmic domain mediates growth factor signals and controls "H(+)-sensing"*. *Proc Natl Acad Sci U S A*, 1992. **89**(6): p. 2424-2428.
121. Thomson, R.B., et al., *Role of PDZK1 in membrane expression of renal brush border ion exchangers*. *Proc Natl Acad Sci U S A*, 2005. **102**(37): p. 13331-6.
122. Kunzelmann, K. and M. Mall, *Electrolyte Transport in the Mammalian Colon: Mechanisms and Implications for Disease*. *Physiol Rev*, 2002. **82**(1): p. 245-289.
123. Clarke, L.L. and M.C. Harline, *CFTR is required for cAMP inhibition of intestinal Na<sup>+</sup> absorption in a cystic fibrosis mouse model*. *Am J Phys Gastrointest Liver Physiol*, 1996. **270**(2): p. G259-G267.
124. Kunzelmann, K., *The cystic fibrosis transmembrane conductance regulator and its function in epithelial transport*, in *Rev Physiol Bioch P1999*, Springer Berlin Heidelberg. p. 1-70.
125. Dharmsathaphorn, K. and S.J. Pandol, *Mechanism of chloride secretion induced by carbachol in a colonic epithelial cell line*. *J Clin Invest*, 1986. **77**(2): p. 348-354.

126. Donowitz, M., *Ca<sup>2+</sup> in the control of active intestinal Na and Cl transport: involvement in neurohumoral action*. Am J Physiol Gastrointest Liver Physiol, 1983. **245**(2): p. G165-G177.
127. Hogan, D.L., et al., *CFTR mediates cAMP- and Ca<sup>2+</sup>-activated duodenal epithelial HCO<sub>3</sub><sup>-</sup> secretion*. Am J Physiol Gastrointest Liver Physiol, 1997. **272**(4): p. G872-G878.
128. Seidler, U., et al., *A functional CFTR protein is required for mouse intestinal cAMP-, cGMP- and Ca(2+)-dependent HCO<sub>3</sub><sup>-</sup> secretion*. J Physiol, 1997. **505**(Pt 2): p. 411-423.
129. Zachos, N.C., M. Tse, and M. Donowitz, *Molecular physiology of intestinal Na<sup>+</sup>/H<sup>+</sup> exchange*. Annu Rev Physiol, 2005. **67**: p. 411-43.
130. Akhter, S., et al., *C-Terminal Domains of Na<sup>+</sup>/H<sup>+</sup> Exchanger Isoform 3 Are Involved in the Basal and Serum-Stimulated Membrane Trafficking of the Exchanger*. Biochemistry, 2000. **39**(8): p. 1990-2000.
131. D'Souza, S., et al., *The Epithelial Sodium-Hydrogen Antiporter Na<sup>+</sup>/H<sup>+</sup> Exchanger 3 Accumulates and Is Functional in Recycling Endosomes*. J Biol Chem, 1998. **273**(4): p. 2035-2043.
132. Janecki, A.J., et al., *Subcellular Redistribution Is Involved in Acute Regulation of the Brush Border Na<sup>+</sup>/H<sup>+</sup> Exchanger Isoform 3 in Human Colon Adenocarcinoma Cell Line Caco-2*. J Biol Chem, 1998. **273**(15): p. 8790-8798.
133. Donowitz, M., et al., *NHERF family and NHE3 regulation*. J Physiol, 2005. **567**(1): p. 3-11.
134. Donowitz, M. and X. Li, *Regulatory Binding Partners and Complexes of NHE3*. Physiol Rev, 2007. **87**(3): p. 825-872.
135. Murtazina, R., et al., *NHERF2 is necessary for basal activity, second messenger inhibition, and LPA stimulation of NHE3 in mouse distal ileum*. Am J Physiol-Cell Physiol, 2011. **301**(1): p. C126-C136.
136. Cinar, A., et al., *NHE3 inhibition by cAMP and Ca<sup>2+</sup> is abolished in PDZ-domain protein PDZK1-deficient murine enterocytes*. J Physiol, 2007. **581**(3): p. 1235-1246.

137. Hillesheim, J., et al., *Down regulation of small intestinal ion transport in PDZK1- (CAP70/NHERF3) deficient mice*. Pflug Arch Eur J Physiol, 2007. **454**(4): p. 575-586.
138. Zachos, N.C., et al., *Elevated intracellular calcium stimulates NHE3 activity by an IKEPP (NHERF4) dependent mechanism*. Cel Physiol Biochem, 2008. **22**(5-6): p. 693-704.
139. Walsh, D.E., B.J. Harvey, and V. Urbach, *CFTR regulation of intracellular calcium in normal and cystic fibrosis human airway epithelia*. J Membr Biol, 2000. **177**(3): p. 209-19.
140. Ahn, W., et al., *Regulatory Interaction between the Cystic Fibrosis Transmembrane Conductance Regulator and HCO Salvage Mechanisms in Model Systems and the Mouse Pancreatic Duct*. J Biol Chem, 2001. **276**(20): p. 17236-17243.
141. Bretscher, A. and K. Weber, *Localization of actin and microfilament-associated proteins in the microvilli and terminal web of the intestinal brush border by immunofluorescence microscopy*. J Cell Biol, 1978. **79**(3): p. 839-45.
142. Brown, J.W. and C.J. McKnight, *Molecular model of the microvillar cytoskeleton and organization of the brush border*. PLoS ONE, 2010. **5**(2): p. e9406.
143. Bretscher, A. and K. Weber, *Fimbrin, a new microfilament-associated protein present in microvilli and other cell surface structures*. J Cell Biol, 1980. **86**(1): p. 335-40.
144. Bretscher, A. and K. Weber, *Villin is a major protein of the microvillus cytoskeleton which binds both G and F actin in a calcium-dependent manner*. Cell, 1980. **20**(3): p. 839-47.
145. Collins, J.H. and C.W. Borysenko, *The 110,000-dalton actin- and calmodulin-binding protein from intestinal brush border is a myosin-like ATPase*. J Biol Chem, 1984. **259**(22): p. 14128-35.
146. Coluccio, L.M. and A. Bretscher, *Calcium-regulated cooperative binding of the microvillar 110K-calmodulin complex to F-actin: formation of decorated filaments*. J Cell Biol, 1987. **105**(1): p. 325-33.

147. McConnell, R.E. and M.J. Tyska, *Myosin-1a powers the sliding of apical membrane along microvillar actin bundles*. J Cell Biol, 2007. **177**(4): p. 671-81.
148. Cereijido, M., R.G. Contreras, and L. Shoshani, *Cell adhesion, polarity, and epithelia in the dawn of metazoans*. Physiol Rev, 2004. **84**(4): p. 1229-62.
149. Paladino, S., et al., *Oligomerization is a specific requirement for apical sorting of glycosyl-phosphatidylinositol-anchored proteins but not for non-raft-associated apical proteins*. Traffic, 2007. **8**(3): p. 251-8.
150. Delacour, D., et al., *Galectin-4 and sulfatides in apical membrane trafficking in enterocyte-like cells*. J Cell Biol, 2005. **169**(3): p. 491-501.
151. Delacour, D., et al., *Apical sorting by galectin-3-dependent glycoprotein clustering*. Traffic, 2007. **8**(4): p. 379-88.
152. Mishra, R., et al., *Galectin-9 trafficking regulates apical-basal polarity in Madin-Darby canine kidney epithelial cells*. Proc Natl Acad Sci U S A, 2010. **107**(41): p. 17633-17638.
153. Lingwood, D. and K. Simons, *Lipid Rafts As a Membrane-Organizing Principle*. Science, 2010. **327**(5961): p. 46-50.
154. Scheiffele, P., J. Peranen, and K. Simons, *N-glycans as apical sorting signals in epithelial cells*. Nature, 1995. **378**(6552): p. 96-8.
155. Yeaman, C., et al., *The O-glycosylated stalk domain is required for apical sorting of neurotrophin receptors in polarized MDCK cells*. J Cell Biol, 1997. **139**(4): p. 929-40.
156. Tai, A.W., et al., *Rhodopsin's Carboxy-Terminal Cytoplasmic Tail Acts as a Membrane Receptor for Cytoplasmic Dynein by Binding to the Dynein Light Chain Tctex-1*. Cell, 1999. **97**(7): p. 877-887.
157. Lisanti, M.P., et al., *Polarized apical distribution of glycosyl-phosphatidylinositol-anchored proteins in a renal epithelial cell line*. Proc Natl Acad Sci U S A, 1988. **85**(24): p. 9557-9561.
158. Nakatsu, F. and H. Ohno, *Adaptor Protein Complexes as the Key Regulators of Protein Sorting in the Post-Golgi Network*. Cell Struct Funct, 2003. **28**(5): p. 419-429.

159. Owen, D.J. and P.R. Evans, *A Structural Explanation for the Recognition of Tyrosine-Based Endocytotic Signals*. Science, 1998. **282**(5392): p. 1327-1332.
160. Marks, M.S., et al., *Protein sorting by tyrosine-based signals: adapting to the Ys and wherefores*. Trends Cell Biol, 1997. **7**(3): p. 124-128.
161. Sandoval, I.V. and O. Bakke, *Targeting of membrane proteins to endosomes and lysosomes*. Trends Cell Biol, 1994. **4**(8): p. 292-297.
162. Pond, L., et al., *A Role for Acidic Residues in Di-leucine Motif-based Targeting to the Endocytic Pathway*. J Biol Chem, 1995. **270**(34): p. 19989-19997.
163. Braakman, I. and N.J. Bulleid, *Protein folding and modification in the mammalian endoplasmic reticulum*. Annu Rev Biochem, 2011. **80**: p. 71-99.
164. Rapoport, T.A., *Protein transport across the endoplasmic reticulum membrane: Facts, models, mysteries*. FASEB J, 1991. **5**(13): p. 2792-2798.
165. Burgess, T.L. and R.B. Kelly, *Constitutive and regulated secretion of proteins*. Ann Rev Cell Biol, 1987. **3**: p. 243-93.
166. Verdugo, P., et al., *Molecular mechanism of mucin secretion: I. The role of intragranular charge shielding*. J Dent Res, 1987. **66**(2): p. 506-8.
167. Paz, H.B., et al., *The role of calcium in mucin packaging within goblet cells*. Exp Eye Res, 2003. **77**(1): p. 69-75.
168. Perez-Vilar, J., et al., *pH-dependent intraluminal organization of mucin granules in live human mucous/goblet cells*. J Biol Chem, 2005. **280**(17): p. 16868-81.
169. Ambort, D., et al., *Calcium and pH-dependent packing and release of the gel-forming MUC2 mucin*. Proc Natl Acad Sci U S A, 2012. **109**(15): p. 5645-5650.
170. Goldstein, L.S. and Z. Yang, *Microtubule-based transport systems in neurons: the roles of kinesins and dyneins*. Annu Rev Neurosci, 2000. **23**: p. 39-71.
171. Park, J.J. and Y.P. Loh, *How peptide hormone vesicles are transported to the secretion site for exocytosis*. Mol Endocrinol, 2008. **22**(12): p. 2583-2595.

172. Pearse, B.M., *Clathrin: a unique protein associated with intracellular transfer of membrane by coated vesicles*. Proc Natl Acad Sci U S A, 1976. **73**(4): p. 1255-9.
173. Nichols, B.J. and J. Lippincott-Schwartz, *Endocytosis without clathrin coats*. Trends Cell Biol, 2001. **11**(10): p. 406-412.
174. Puri, V., et al., *Clathrin-dependent and -independent internalization of plasma membrane sphingolipids initiates two Golgi targeting pathways*. J Cell Biol, 2001. **154**(3): p. 535-548.
175. Rothberg, K.G., et al., *Caveolin, a protein component of caveolae membrane coats*. Cell, 1992. **68**(4): p. 673-682.
176. Trowbridge, I.S., J.F. Collawn, and C.R. Hopkins, *Signal-dependent membrane protein trafficking in the endocytic pathway*. Ann Rev Cell Biol, 1993. **9**: p. 129-61.
177. Pearse, B.M. and M.S. Robinson, *Clathrin, adaptors, and sorting*. Ann Rev Cell Biol, 1990. **6**: p. 151-71.
178. Chen, M.S., et al., *Multiple forms of dynamin are encoded by shibire, a Drosophila gene involved in endocytosis*. Nature, 1991. **351**(6327): p. 583-586.
179. van der Blik, A.M. and E.M. Meyerowitz, *Dynamin-like protein encoded by the Drosophila shibire gene associated with vesicular traffic*. Nature, 1991. **351**(6325): p. 411-414.
180. Helenius, A., et al., *Endosomes*. Trends Biochem Sci, 1983. **8**(7): p. 245-250.
181. Mayor, S., J.F. Presley, and F.R. Maxfield, *Sorting of membrane components from endosomes and subsequent recycling to the cell surface occurs by a bulk flow process*. J Cell Biol, 1993. **121**(6): p. 1257-1269.
182. Hopkins, C.R., *Intracellular routing of transferrin and transferrin receptors in epidermoid carcinoma A431 cells*. Cell, 1983. **35**(1): p. 321-330.
183. Hopkins, C.R. and I.S. Trowbridge, *Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells*. J Cell Biol, 1983. **97**(2): p. 508-521.



184. Yamashiro, D.J., et al., *Segregation of transferrin to a mildly acidic (pH 6.5) para-golgi compartment in the recycling pathway*. Cell, 1984. **37**(3): p. 789-800.
185. van der Sluijs, P., et al., *The small GTP-binding protein rab4 controls an early sorting event on the endocytic pathway*. Cell, 1992. **70**(5): p. 729-740.
186. Morelle, W., et al., *Glycosylation pattern of brush border-associated glycoproteins in enterocyte-like cells: involvement of complex-type N-glycans in apical trafficking*. Biol Chem, 2009. **390**(7): p. 529-44.
187. Altschuler, Y., et al., *Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state*. Mol Biol Cell, 2000. **11**(3): p. 819-31.
188. Liu, X., Z. Yuan, and M. Chung, *MUC1 intra-cellular trafficking is clathrin, dynamin, and rab5 dependent*. Biochem Biophys Res Commun, 2008. **376**(4): p. 688-693.
189. Kinlough, C.L., et al., *MUC1 membrane trafficking is modulated by multiple interactions*. J Biol Chem, 2004. **279**(51): p. 53071-7.
190. Kinlough, C.L., et al., *Recycling of MUC1 is dependent on its palmitoylation*. J Biol Chem, 2006. **281**(17): p. 12112-22.
191. Lukacs, G.L., et al., *Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP*. Embo J, 1994. **13**(24): p. 6076-86.
192. Ward, C.L., S. Omura, and R.R. Kopito, *Degradation of CFTR by the ubiquitin-proteasome pathway*. Cell, 1995. **83**(1): p. 121-7.
193. Lukacs, G.L., et al., *The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells*. J Biol Chem, 1993. **268**(29): p. 21592-8.
194. Farnen, S.L., et al., *Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl<sup>-</sup> transport and overexpression can generate basolateral CFTR*. Am J Physiol Lung Cell Mol Physiol, 2005. **289**(6): p. L1123-30.
195. Murtazina, R., et al., *Na<sup>+</sup>/H<sup>+</sup> Exchanger NHE3 Activity and Trafficking Are Lipid Raft-dependent*. J Biol Chem, 2006. **281**(26): p. 17845-17855.

196. Chow, C.-W., et al., *The Epithelial Na<sup>+</sup>/H<sup>+</sup> Exchanger, NHE3, Is Internalized through a Clathrin-mediated Pathway*. J Biol Chem, 1999. **274**(53): p. 37551-37558.
197. Jakab, R.L., A.M. Collaco, and N.A. Ameen, *Physiological relevance of cell-specific distribution patterns of CFTR, NKCC1, NBCe1, and NHE3 along the crypt-villus axis in the intestine*. Am J Physiol Gastrointest Liver Physiol, 2011. **300**(1): p. G82-98.
198. Swiatecka-Urban, A., et al., *PDZ domain interaction controls the endocytic recycling of the cystic fibrosis transmembrane conductance regulator*. J Biol Chem, 2002. **277**(42): p. 40099-105.
199. Cheng, J., et al., *A Golgi-associated PDZ domain protein modulates cystic fibrosis transmembrane regulator plasma membrane expression*. J Biol Chem, 2002. **277**(5): p. 3520-9.
200. Cheng, J., et al., *Syntaxin 6 and CAL Mediate the Degradation of the Cystic Fibrosis Transmembrane Conductance Regulator*. Mol Biol Cell, 2010: p. E09-03-0229.
201. Kocher, O., et al., *Targeted disruption of the PDZK1 gene by homologous recombination*. Mol Cell Biol, 2003. **23**(4): p. 1175-80.
202. Shenolikar, S., et al., *Targeted disruption of the mouse NHERF-1 gene promotes internalization of proximal tubule sodium-phosphate cotransporter type IIa and renal phosphate wasting*. Proc Natl Acad Sci U S A, 2002. **99**(17): p. 11470-11475.
203. Broere, N., et al., *Cystic Fibrosis Transmembrane Conductance Regulator Activation Is Reduced in the Small Intestine of Na<sup>+</sup>/H<sup>+</sup> Exchanger 3 Regulatory Factor 1 (NHERF-1)- but Not NHERF-2-deficient Mice*. J Biol Chem, 2007. **282**(52): p. 37575-37584.
204. O'Shannessy, D.J., M.J. Dobersen, and R.H. Quarles, *A novel procedure for labeling immunoglobulins by conjugation to oligosaccharide moieties*. Immunol Lett, 1984. **8**(5): p. 273-277.
205. Dinkel, H., et al., *ELM—the database of eukaryotic linear motifs*. Nucleic Acids Res, 2011.
206. Gentzsch, M., et al., *The PDZ-binding chloride channel ClC-3B localizes to the Golgi and associates with cystic fibrosis transmembrane conductance*

- regulator-interacting PDZ proteins*. J Biol Chem, 2003. **278**(8): p. 6440-9.
207. Uhlén, M., et al., *A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody Proteomics*. Mol Cell Proteomics, 2005. **4**(12): p. 1920-1932.
208. Uhlen, M., et al., *Towards a knowledge-based Human Protein Atlas*. Nat Biotech, 2010. **28**(12): p. 1248-1250.
209. Tonikian, R., et al., *A specificity map for the PDZ domain family*. PLoS Biol, 2008. **6**(9): p. e239.
210. Stiffler, M.A., et al., *PDZ domain binding selectivity is optimized across the mouse proteome*. Science, 2007. **317**(5836): p. 364-9.
211. Grubb, B.R. and R.C. Boucher, *Pathophysiology of Gene-Targeted Mouse Models for Cystic Fibrosis*. Physiol Rev, 1999. **79**(1): p. S193-S214.
212. Gustafsson, J.K., et al., *An ex vivo method for studying mucus formation, properties, and thickness in human colonic biopsies and mouse small and large intestinal explants*. Am J Physiol Gastrointest Liver Physiol, 2012. **302**(4): p. G430-G438.
213. Lillehoj, E.P., et al., *Pseudomonas aeruginosa stimulates phosphorylation of the airway epithelial membrane glycoprotein Mucl and activates MAP kinase*. Am J Physiol Lung Cell Mol Physiol, 2004. **287**(4): p. L809-15.
214. Afrin, R., et al., *Extraction of membrane proteins from a living cell surface using the atomic force microscope and covalent crosslinkers*. Cell Biochem Biophys, 2003. **39**(2): p. 101-17.
215. Hill, D.B., et al., *Force Generation and Dynamics of Individual Cilia under External Loading*. Biophys J, 2010. **98**(1): p. 57-66.
216. Kubitschek, H.E., *Cell volume increase in Escherichia coli after shifts to richer media*. J Bacteriol, 1990. **172**(1): p. 94-101.
217. McDole, J.R., et al., *Goblet cells deliver luminal antigen to CD103+ dendritic cells in the small intestine*. Nature, 2012. **483**(7389): p. 345-349.
218. Argueso, P., et al., *Association of cell surface mucins to galectin-3 contributes to the ocular surface epithelial barrier*. J Biol Chem, 2009. **284**(34): p. 23037-45.